リウマチ病セミナー XI

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,840 円(税込)

購入する

商品紹介

数多いリウマチ患者を専門的に扱う医者が必要なことは言うまでもない。この医者は四肢・脊椎の骨・関節に関する広い知識と治療手技を身につけていなければならない。まずうまく診断できて、その病気の予後についてよくわかっている必要がある。本書ではこのようなリウマチ医の期待に応えられるように心がけてテーマを選択した。（序文より）

目次

  • 表紙
  • 執筆者一覧
  • 序文
  • 目次
  • 炎症リウマチ
  • 結節性多発動脈炎と顕微鏡的多発血管炎
  • 新しい炎症性ミオパチー macrophagic myofasciitis
  • SLEと妊娠
  • サルコイドーシスの皮膚病変
  • 骨関節, 脊椎, 神経
  • 股関節症の疫学
  • Gorham's disease
  • myositis ossificans progressiva (fibrodysplasia ossificans progressiva)
  • paraneoplastic syndromeとしてのリウマチ病
  • chondrodysplasia 1999
  • 透析に関連して出現するリウマチ症状
  • 仙腸関節の解剖病理
  • histiocytosis
  • hyperlipidemiaとリウマチ症状
  • 燐・カルシウム代謝
  • 骨粗鬆症とselective estrogen receptor modulators
  • 低リン血症
  • 骨粗鬆症の遺伝子
  • 検査法
  • MRアンギオグラフィー
  • 生物学的反応
  • 補体系とリウマチ病
  • 慢性関節リウマチの病因遺伝子
  • 一酸化窒素(NO)と関節炎
  • 軟骨の再生
  • 治療と副作用
  • RAに対するステロイド経口投与療法の位置づけ
  • 新しいDMARDs
  • 頸椎の神経ブロック療法
  • リウマチ性疾患の疼痛対策
  • 膝関節OAの関節洗浄効果
  • 脊髄損傷と治療適応-神経組織破壊防止から残存神経賦活-
  • 抗菌剤と炎症リウマチ
  • 患者教育
  • 手術
  • 整形外科における生体材料の進歩-人工関節軟骨の開発-
  • 新しい指人工関節
  • 索引(XI)
  • 総索引(I～XI)
  • DRUG INFORMATION
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.7 掲載の参考文献
1) 難治性血管炎調査研究班: 結節性動脈周囲炎. 「難病の診断と治療指針」 (厚生省保健医療局疾病対策課, 監修), pp107-115, 東京, 六法出版社, 1997
 
2) 橋本博史, 矢野哲郎, 安倍達ら: 中・小型血管炎の全国疫学調査. 厚生省特定疾患難治性血管炎調査研究班, 1995年度研究報告書, pp9-21, 1996
 
3) Sobajima J, Ozaki S, Osakada F, et al: Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis; Non-histone chromosomal proteins, HMGI and HMG2. Clin Exp Immunol 107: 135-140, 1997
PubMed
4) Sobajima J, Ozaki S, Okazaki T, et al: Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis; Anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol 105: 120-124, 1996
 
5) Sobajima J, Ozaki S, Uesugi H, et al: High mobility group non-histone chromosomal proteins HMGI and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic anti-bodies in autoimmune hepatitis. Gut 44: 867-873, 1999
 
6) Sobajima J, Ozaki S, Uesugi H, et al: Prevalence and characterization of P-ANCA directed against HMGI and HMG2 in ulcerative colitis. Clin Exp Immunol 111: 402-407, 1998
 
7) Uesugi H, Ozaki S, Sobajima J, et al: Prevalence and characterization of novel P-ANCA, antibodies to the high mobility group non-histone chromosomal proteins HMGI and HMG2, in systemic rheumatic diseases. J Rheumatol 25: 703-709, 1998
 
8) 尾崎承一, 傍島淳子, 上杉裕子ら: ANCA関連血管炎における抗HMG1/HMG2抗体. 厚生省特定疾患免疫疾患調査研究班, 難治性血管炎分科会, 1998年度研究報告書, pp135-142, 1999
 
9) Merenmies J, Pihlaskari R, Laitinen J, et al: 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth; Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem 266: 16722-16729, 1991
PubMed
10) Taguchi A, Blood DC, del Toro C, et al: Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastases. Nature 405: 354-360, 2000
 
11) Melloni E, Sparatore B, Patrone M, et al: Extracellular release of the "differentiation enhancing factor", a HMGI protein type, is an early step in murine erythroleukemia cell differentiation. FEBS Lett 368: 466-470, 1995
 
12) Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999
PubMed
13) Hori O, Brett J, Slattery S, et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 270: 25752-25761, 1995
 
14) Hofmann MA, Drury S, Fu C, et al: RAGE mediates a novel proinflammatory axis; A central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901, 1999
 
P.12 掲載の参考文献
1) Gherardi RK, Conquet M, Cherin P, et al: Macrophagic myofasciitis: an emerging entity. Lancet 352: 347-352, 1998
 
2) Dalakas MC: Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 325: 1487-1498, 1991
PubMed
3) Cherin P, Gherardi R, Meyer O: La myofasciite a macrophages: une nouvelle entite. I'Actualite Rhumatologique 1999 (Eds, Kahn MF, Kuntz D, Meyer O, et al), pp88-94, Paris, Expansion, 1999
 
4) Cherin P, Gherardi RK, the GERMMAD (Study group of the French association against myopathies); Emergence of a new entity, the macrophagic myofasciitis. Rev Rhum 65: 541-542, 1998
 
5) Naschitz JE, Boss JH, Misselevich I, et al: The fasciitis-panniculitis syndromes. clinical and pathologic features. Medicine 75: 6-16, 1996
PubMed
6) Schulman LE: Diffuse fasciitis with hypergammaglobulinemia and eosinophilia. a new syndrome. J Rheumatoll (Suppl): 56, 1975
 
7) Kilbourne EM, Rigau-perez JG, Heath JrCW, et al: Clinical epidemiology of toxic-oil syndrome. manifestation of a new illness. N Engl J Med 309: 1408-1414, 1983
PubMed
8) Hertzman PA, Blevins WL, Mayer J, et al: Association of the eosinophilia. myalgia syndrome with the ingestion of tryptophan. N Engl J Med 322: 869-873, 1990
PubMed
9) Swash M, Schwartz MS, Vandenberg MJ, et al: Myopathy in Whipple's disease, Gut 18, 800-804, 1977
 
10) Cherin P, Gherardi R, Conquet M, et al: Macrophagic myofasciitis: role of intramuscular injections of aluminum-containing vaccines? Proceeding of 12th French congress of rheumatology, p585, 1999
 
P.22 掲載の参考文献
1) Amadori A, Zamarchi R, DeSilvestro G, et al: Genetic Control of the CD4/CD8 T-cell ratio in humans. Nature Med 1: 1279-83, 1995
 
2) Mosmann TR, Cherwinski H, Bond MW, et al; Two types of mouse helper T cells. I. Definition of according to profiles of lymphokine activities and secrete proteins. J Immunol 136: 2348-2357, 1986
PubMed
3) Buyon JP, Nelson JL, Lockshin MD: The effects of pregnancy on autoimmune diseases. Clin Immunol Immunopathol 78: 99-104, 1996
PubMed
4) Reinhard G, Noll A, Schlebusch H, et al: Shifts in the THI/TH2 balance during human pregnancy correlate with apoptotic changes. Biochem Biophys Res Commun 28: 933-938, 1998
 
5) Russell AS, Johnston C, Chew C, et al: Evidence for reduced Th1 function in normal pregnancy; A hypothesis for the remission of rheumatoid arthritis. J Rheumatol 24: 1045-1050, 1997
PubMed
6) 石田博, 大田博之, 柳田英寿ら: Th1介在自己免疫病とTh2介在自己免疫病. 日本臨牀55: 1438-1443, 1997
 
7) Jorgensen C, Picot MC, Bologna C, et al: Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis 55: 94-98, 1996
PubMed
8) Whitacre CC, et al: (Full Text) Sex Differences in Autoimmune disease; Focus on Multiple Sclerosis. The Task Force on Gender, Multiple Sclerosis and Autoimmunity. Science Supplementary Mat-erial. http: //www.sciencemag.org/feature/data/983519.shl (Summary), A Gender Gap in Autoimmunity. Science 283: 1277-1278, 1999
 
9) Nelson JL, Hughes KA, Smith AG, et al: Remission of rheumatoid arthritis during pregnancy and maternal-fetal class II alloantigen disparity. Am J Reprod Immunol 28: 226-227, 1992
PubMed
10) Nelson JL, Furst DE, Maloney S, et al: Microchimerism and HLA-compatible relationships of pr-egnancy in scleroderma. Lancet 351: 559-562, 1998
 
11) 中山雅弘: 自己免疫疾患合併妊婦の胎盤病理所見. 周産期学シンポジウム9: 55, 1991
 
12) Lockitch G (ed): Handbook of Diagnostic Biochemistry and Hematology in Normal Pregnancy. I.F. 9～10. CRC Press, Ann Arbor, 1993
 
13) Litsey SE, Noonan JA, O'Connor WN, et al: Maternal connective tissue disease and congenital heart block. Demonstration of immunoglobulin in cardiac tissue. New Engl J Med 312: 98-100, 1985
PubMed
14) Buyon JP, Winchester RJ, Slade SG, et al: Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthr Rheumat 36: 1263-1273, 1993
 
15) Shinohara K, Miyagawa S, Fujita T, et al: Neonatal Lupus Erythematosus; Results of Maternal Corticosteroid Therapy. Obstet Gynecol 93: 952-957, 1999
PubMed
16) Miyagawa S, Shinohara K, Kidoguchi K, et al: Neonatal Lupus Erythernatosus; Studies on HLA Class II Genes and Autoantibody Profiles in Japanese Mothers. Autoimmunity 26: 95-101, 1997
PubMed
17) 津田裕士, 宮方了, 河西利昭ほか: SS-A抗体SS-B抗体とアフェレーシス療法. 日本アフェレーシス学会雑誌16: 398-399, 1997
 
18) 鏑木淳一: 抗リン脂質抗体症候-抗体の特異性と血栓症-, 日本臨床免疫学会雑誌22: 1-12, 1999
 
19) Nakamura N, Kuragaki C, Shidara Y, et al: Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am J Hematol 49: 347-348, 1995
PubMed
P.27 掲載の参考文献
1) 立花暉夫: サルコイドーシスの全国臨床統計. 日本臨牀52: 1508-1515, 1994
 
2) James DG, WL Epstein: Cutaneous sarcoidosis. In: Lung Biology in Health and Disease Vol 73 Sarcoidosis and other granulomatous disorders (Ed, James DG), pp311-322, New York, Marcel Dekkar Inc, 1994
 
3) Lynch JP, Sharma Om P, Baughman RP: Extrapulmonary sarcoidosis. Sem in Resp Inf 13: 229-254, 1998
 
4) Johns CJ, Michele TH: The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine 78: 65-111, 1999
 
5) 岡本祐之: サルコイドーシスの皮膚病変の多様性. 日本サ学会雑誌16: 34-35, 1997
 
6) Rizzato G, Montemurto L: The locomotor system. I The bone, II The joints, III The skeletal muscles. In: Lung Biology in Health and Disease Vol 73 Sarcoidosis and other granulomatous disorders (Ed, James DG), pp 349-374, New York, Marcel Dekkar Inc, 1994
 
7) 木下正子, 川田陽弘: 小児サルコイドーシス-苔癬様角化性皮疹を示した2例-. 臨皮31: 807-811, 1977
 
8) 伊東重光, 加藤瑠璃子, 浅野喜造ら: 肝脾腫を主訴とした幼児のサルコイドーシスの1例. 小児科18: 613-619, 1977
 
9) 樋口由美子, 西山千秋, 森嶋隆文: 水痘後の瘢痕後に一致して皮疹が生じたサルコイドーシスの幼児例. 臨皮45: 137-141, 1991
 
10) 田中幸子, 堀啓一郎, 川上淳子: 乳児期発症のサルコイドーシス. 皮膚34: 1-2, 1992
 
11) 川上淳子, 大久保潔, 高井和子ら: 小児にみられたサルコイドーシスの1例. 眼紀42: 1393-1398, 1991
 
12) Ukae S, Tsutsumi H, Adachi N, et al: Preschool sarcoidosis manifesting as juvenile rheumatoid arthritis; Acase report and a review of the literature of Japanese cases. Acta Paediatrica Japonica 36: 515-518, 1994
 
13) Tachibana T, Yamamoto M, Izumi T, et al: Re-evaluation of the prognostic significance of sarcoidosis of acute onset. In Sarcoidosis and other granulomatous diseases (Ed, Williams WJ, Davies BM), pp547-550, Cardiff, Alpha Omega Publ Ltd, 1980
 
14) 立花暉夫: サルコイドーシスの急性発症. 臨床医7: 1912-1913, 1981
 
15) 斉藤潤, 井上康二, 小宮靖弘ら: 関節症状を呈したサルコイドーシスの1例. 整形外科43: 971-973, 1992
 
16) 志摩清, 岳中耐夫, 田中不二穂: 骨・関節病変. 最近のサルコイドーシス, 日本サルコイドーシス学会編, pp98-99, 東京, 現代医療社, 1993
 
17) 平賀洋明: 骨病変を呈した13年以上の経過例. 最近のサルコイドーシス. 日本サルコイドーシス学会編,pp 100-101, 東京, 現代医療社, 1993
 
18) 立花暉夫, 秋元隆道, 岡野昌樹ら: 皮膚病変を有するサルコイドーシス長期経過追求例. 日本サルコイドーシス/肉芽腫性疾患学会雑誌 19: 33-37, 1999
 
19) 市丸勝二, 今給黎篤弘, 三浦幸雄: 著しい指変形を伴うサルコイドーシス症例について. 整形外科32: 1704-1706, 1981
 
20) 小林衣子, 高島厳, 平賀洋明: 多彩な皮膚症状を呈したサルコイドーシスの1例. 日本皮膚科学会誌99: 353, 1989 (会)
 
21) 吉川義顕, 岡本祐之, 今村貞夫: 骨病変を伴ったびまん浸潤型サルコイドーシスの1例. 皮膚科紀要88: 465-468, 1993
 
22) 前田剛, 西崎弘, 細谷茂樹ら: サルコイドーシスにおける骨病変-自験例4例の検討日本サルコイドーシス学会誌8: 121-122, 1989
 
23) 山崎正視, 比留間政太郎, 高橋洋文ら: び漫浸潤型皮膚サルコイドーシスの1例. 日本皮膚科学会誌103: 582, 1993 (会)
 
24) 山本正彦: 骨・関節・筋肉のサルコイドーシス. 最新医学27: 1279-1285, 1972
 
25) 福代良一.: サルコイドーシス-骨病変を伴った症例-. 皮膚病臨床10: 603-606, 1988
 
26) 車谷峰子, 山川全一: 骨病変を伴ったサルコイドーシスの1例. 皮膚臨床25: 1217-1221, 1983
 
27) 坂田憲史, 永田真, 倉光薫ら: 多発性骨病変を認めたサルコイドーシスの1例. 呼吸11: 1324-1329, 1992
 
28) 木村英二, 後藤秀樹, 西山進ら: 顔面紅斑が端緒となった肺, 心, 骨, 神経サルコイドーシス. 皮膚病診療 15: 138-142, 1993
 
29) 上田美鶴, 足立あゆみ: 破壊性骨病変を伴ったサルコイドーシスの1例. 日本皮膚科学会誌106: 1253-1254, 1995 (会)
 
30) Iwai K, Tachibana T, Takemura Y, et al: Pathological studies on sarcoidosis autopsy, I. Epideminological features of 320 cases in Japan. Acta Path Jap 43: 372-376, 1993
 
31) 立花暉夫: サルコイドーシスにおける肝障害. 肝胆疾患-新しい診断. 治療体系-日本臨牀46 (増刊号): 458-464, 1988
 
32) 多祢直美, 林満壽彦, 佐古田新ら: 関節症状を主訴として長期間経過中にサルコイド病変をみた1症例. リウマチ20: 358-366, 1980
 

骨関節, 脊椎, 神経

P.35 掲載の参考文献
1) Murray RO: The oetiology of primary osteoarthritis of the hip. Br J Radiol 38: 810-824, 1965
 
2) Solomon L: Patterns of osteoarthritis of the hip. J Bone Joint Surg 58-B: 176-183, 1976
 
3) 大田寛: 関節症の有病率に関する調査研究: 特にX線的股関節症を中心に, 日整会誌53: 27-42, 1979
 
4) Inoue K, Shichikawa K, Ota H: Prevalence of hip osteoarthritis in Kamitonda; From a longitudinal population-based epidemiological study of rheumatic diseases in Japan. Rheumatol 38: 793-794, 1999
 
5) Kellgren JH, Lawrence JS: Osteoarthrosis and disc degeneration in an urban population. Ann Rheum Dis 17: 388-397, 1958
 
6) Kellgren JH, Lawrence JS: Osteoarthrosis of the hip in random population sample. Communicazi-one al Congresso della Lega Internationale contro il Rheumatismo. Rome, 1961
 
7) Lawrence RC, Hochberg MC, Kelsey JL, et al: Estimates of the prevalence of selected arthritis and musculoskeletal diseases in the United States. J Rheumatol 16: 427-441, 1989
PubMed
8) Van Sasse JLCM, Van Romunde LKJ, Cats A, et al: Epidemiology of osteoarthritis; Zoetermeer survey. Comparison of radiologic osteoarthritis in a Dutch population with that in 10 other popul-ations. Ann Rheum Dis 48: 271-280, 1989
 
9) Hoaglund FT, Yan ACMC, Wong WL: Osteoarthritis of the hip and other joints in Southern Chinese in Hong Kong. J Bone Joint Surg 55-A: 545-557, 1973
 
10) Yoshimura N, Campbell L, Hashimoto T, et al: Acetabular dysplasia and hip osteoarthritis in Britain and Japan. Br J Rheumatol 37: 1193-1197, 1998
PubMed
11) Croft P, Cooper C, Wickham C, et al: Osteoarthritis of the hip and acetabular dysplasia. Ann Rh-eum Dis 50: 308-310, 1991
 
12) Smith RW, Egger P, Coggon D, et al: Osteoarthritis of the hip joint and acetabular dysplasia in women, Ann Rheum Dis 54: 179-181, 1995
PubMed
13) Lau EMC, Lin F, Lam D, et al: Hip osteoarthritis and dysplasia in Chinese men. Ann Rheum Dis 54: 965-969, 1995
 
14) Ali-Gombe A, Croft PR, Silman AJ: Osteoarthritis of the hip and acetabular dysplasia in Nigerian Men. J Rheumatol 23: 512-515, 1996
 
15) Inoue K, Wicart P, Kawasaki T, et al: Prevalence of hip osteoarthritis and acetabular dysplasia in French and Japanese adults. Rheumatol 39: 745-748, 2000
 
P.44 掲載の参考文献
1) Jachson JBS: Aboneless arm. Boston Medical and Surgical Journal 18: 368-369, 1838
 
2) Gorham LW, Stout AP: Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone) its relation to hemangiomatosis. J Bone Joint Surg [Am] 37: 985-1004, 1955
PubMed
3) Manisali M, Ozakksoy D: Gorham disease; Correlation of MR findings with histopathologic changes. Eur Radio 18: 1647-1650, 1998
 
4) Devlin RD, Bone III HG, Roodman GD: Interleukin-6; A potential mediator of the massive osteolysis in patients with Gorham-Stout disease. J Clin Endocrinol Metab 81: 1893-1897, 1996
 
5) Aoki M, Kato F, Saito H, et al: Successful treatment of chylothorax by bleomycin for Gorham's disease. Clin Orthop 330: 193-197, 1996
PubMed
6) Saraux A, Menard N, Ehrhart D, et al: Inflammatory Gorham disease. Rev Rhum [Engl Ed] 60: 516-518, 1993
 
7) Campbell J, Almond HGA, Johnson R: Massive osteolysis of the humerus with spontaneous recovery. Report of a case. J Bone Joint Surg [B] 57: 238-240, 1975
 
8) Heyden G, Kindblom LG, Moeller Nielsen J: Disappearing bone disease. A clinical and histological study. J Bone Joint Surg [Am] 59: 57-61, 1977
 
9) Sage MR, Allen PWL: Massive osteolysis; Report of a case. J Bone Joint Surg [Br] 56: 130-135, 1974
 
10) Cannon SR: Massive osteolysis. A review of seven case. J Bone Joint Surg [Br] 68: 24-28, 1986
 
11) Dickson GR, Mollan RAB, Carr KE: Cyrochemical localization of alkaline and acid phosphatase in human vanishing bone disease. Histochemistry 87: 569-572, 1987
 
12) Spieth ME, Greenspan A, Forrester DM, et al: Gorham's disease of the radius; Radiographic, scintigraphic, and MRI findings with pathologic correlation. A case report and review of the literature. Skeletal Radiol 26: 659-663, 1997
PubMed
13) Shives TC, Beabout JW, Unni KK: Massive osteolysis. Clin Orthop 250: 297-302, 1990
 
14) Mawk JR, Obukhov SK, Nichols WD, et al: Successful conservative management of Gorham disease of the skull base and cervical spine. Child's Nerv Syst 13: 622-625, 1997
 
15) Johnson PM, McClure JG: Observations on massive osteolysis. Radiology 71: 28-42, 1958
PubMed
16) Dan'ura T, Ozaki T, Sugihara S, et al: Massive osteolysis in the pelvis; A case report. Acta Orthop Scand 69: 197-198, 1998
PubMed
17) Halliday DR, Dahlin DC, Pugh DG, et al: Massive osteolysis and angiomatosis. Radiology 82: 637-644, 1964
PubMed
18) Lynch Jr TJ: Management of malignant pleural effusions, Chest 103 (Supple): 385S-389S, 1993
 
19) Hagberg H, Lamberg K: α-2b interferon and oral clodronate for Gorham's disease. Lancet 350: 1822-1823, 1997
 
P.50 掲載の参考文献
1) Shore EM, Glaser DL, Gannon FH: Osteogenic induction in hereditary disorders of heterotopic ossification. Clin Orthop 374: 303-316, 2000
PubMed
2) Magryta CJ, Kligora CJ, Temple HT, et al: Clinical presentation of fibrodysplasia ossificans progressiva: pitfalls in diagnosis. J Pediatr Hematol Oncol 21: 539-543, 1999
PubMed
3) Smith R: Fibrodysplasia (myositis) ossificans progressiva. Clinical lessons from a rare disease. Clin Orthop 346: 7-14, 1998
PubMed
4) Kussmaul WG, Esmail AN, Sagar Y, et al: Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin Orthop 346: 104-109, 1998
PubMed
5) 奥野徹子, 吉田健治, 田中公次ら: 進行性骨化性筋炎-自験例2例と本邦82症例の検討-. 整形外科32: 1837-1843, 1981
 
6) Gannon FH, Valentine BA, Shore EM, et al: Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin Orthop 346: 19-25, 1998
 
7) Gannon FH, Kaplan FS, Olmsted E, et al: Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum Pathol 28: 339-343, 1997
PubMed
8) Shafritz AB, Shore EM, Gannon FH, et al: Over expression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 22; 335: 555-561, 1996
 
9) Lanchoney TF, Olmsted EA, Shore EM, et al: Characterization of bone morphogenetic protein 4 receptor in fibrodysplasia ossificans progressiva. Clin Orthop 346: 38-45, 1998
PubMed
10) Xu M, Shore EM: Mutational screening of the bone morphogenetic protein 4 gene in a family with fibrodysplasia ossificans progressiva. Clin Orthop 346: 53-58, 1998
 
11) Virdi AS, Shore EM, Oreffo RO, et al: Phenotypic and molecular heterogeneity in fibrodysplasia ossificans progressiva. Calcif Tissue Int 65: 250-255, 1999
PubMed
12) Kaplan F, Sawyer J, Connors S, et al: Urinary basic fibroblast growth factor. A biochemical marker for preosseous fibroproliferative lesions in patients with fibrodysplasia ossificans progressiva. Clin Orthop 346: 59-65, 1998
PubMed
13) Olmsted EA, Gannon FH, wang ZQ, et al: Embryonic overexpression of the c-Fos protooncogene, A murine stem cell chimera applicable to the study of fibrodysplasia ossificans progressiva in humans. Clin Orthop 346: 81-94, 1998
 
14) Lucotte G, Semonin O, Lutz P: A de novo heterozygous deletion of 42 base-pairs in the noggin gene of a fibrodysplasia ossificans progressiva patient. Clin Genet 56: 469-470, 1999 (No abstract available)
 
15) Feldman G, Li M, Martin S, et al: Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4 q27-31. Am J Hum Genet 66: 128-135, 2000
 
16) Glaser DL, Rocke DM, Kaplan FS: Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin Orthop 346: 110-116, 1998
PubMed
P.58 掲載の参考文献
1) Simpson JA: Myasthenia gravis; Anew hypothesis. Scott Med J 5: 419, 1960
 
2) Noda M, et al: Structural homology of Torpedo californica acetylcholine receptor subunits. Nature 302: 528, 1983
PubMed
3) Sakmann B, et al: Role of acetylcholine receptor subunits in gating of the channel. Nature 318: 538 1985
PubMed
4) 本村正勝: カルシウムチャネル抗体とLambert-Eaton筋無力症候群. 神経研究の進歩41: 268, 1997
 
5) Calabro JJ: Cancer and arthritis. Arthritis Rheum 10: 553-567, 1967
PubMed
6) Butler RC, Thompson JM, Keat ACS: Paraneoplastic rheumatic disorders; A review, J Royal Soc Med 8: 168-172, 1987
 
7) Caldwell SD, McCallum RM: Rheumatologic manifestations of cancer. Med Clin North Am 70: 385-417, 1986
 
8) Nashitz JE, Yeshurun D, Rosner I: Rheumatic manifestations of occult cancer. Cancer 75: 2954-2958, 1995
 
9) Nashitz JE, Rosner l, Rozenbaum M, et al: Rheumatic syndromes; Clues to occult neoplasia. Semin Arthritis Rheum 29: 43-55, 1999
 
10) Mackenzie AH, Scherbel AL: Connective tissue syndromes associated with carcinoma. Geriatrics 18: 745-753, 1963
PubMed
11) Sheon RP, Kirsner AB, Tangsintanapas P, et al: Malignancy in rheumatic disease; Interrelationships. J Am Geriat Soc 25: 2-27, 1977
 
12) Masin N, Buchard PA, Gerster JC: Polymyalgia rheumatica et cancer pulmonaire; Syndrome paraneoplasique. Rev Rhum 59: 153-154, 1992
PubMed
13) Drenth JPH, Dekleijn EHMA, DeMulber PHM, et al: Metastatic breast cancer presenting as fever, rash, and arthritis. Cancer 75: 1608-1611, 1995
 
14) Greer JM, Longley S, Edwards L, et al: Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine 67: 220-230, 1988
 
15) Farcet JP, Weschsler J, Wirquin V, et al: Vasculitis in hairy cell leukemia. Arch Intern Med 147: 660-664, 1987
PubMed
16) Poveda F, Gonzalez-Garcia J, Picazo ML, et al: Systemic polyarteritis nodosa as the initial manifestation of a gastric adenocarcinoma. J Intern Med 236: 679-683, 1994
PubMed
17) Sanchez-Guerrero J, Gutierrez-Urena S, Vidaller A, et al: Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of literature. J Rheumatol 17: 1458-1462, 1990
PubMed
18) De Cross AJ, Sahasrabudhe DM: Paraneoplastic Raynaud's phenomenon. Am J Med 92: 571-572, 1992
PubMed
19) Chow SF, Mckenna CH: Ovarian cancer and gangrene of the digits; Case report and review of the literature. Mayo Clin Proc 71: 253-258, 1996
PubMed
20) Kohli M, Bennett RM: Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma. J Rheumatol 22: 1393-1394, 1995
PubMed
21) 前田恵治, 調裕次, 五十嵐敢: 皮膚筋炎・多発筋炎と癌. リウマチ病セミナー (七川歡次監修), pp33-41, 大阪, 永井書店, 1997
 
22) Vosskamper M, Korf B, Franke F, et al: Paraneoplastic neoritizig myopathy; Arare discorder to be differentiated from polymyositis. J Neurol 236: 489-492, 1989
 
23) Brownell B, Hughes JT: Degeneration of muscle in association with carcinoma of the bronchus. J Neurol Neurosurg Psychiatry 38: 363-370, 1975
PubMed
24) Smith B: Skeletal neurosis associated with cancer. J Pathol 97: 202-210, 1969
 
25) MacGuigan L, Fleming A: Pericardial mesothelioma presenting as systemic lupus erythematosus. Ann Rheum Dis 43: 515-517, 1984
 
26) Saxne T, Turesson I, Wollheim FA: Preleukemic syndrome simulating SLE. A case report. Acta Med Scand 212: 421-424, 1982
PubMed
27) Kahn MF, Solnica J, Bourgeois P: Disappearance of clinical and biological evidence of SLE after removal of an ovarian seminoma; 21 years follow-up. J Rheumatol B: 833-834, 1986
 
28) Schumacher HR: Articular manifestations of hypertrophic osteoarthropathy In bronchogenic carcinoma. Arthritis Rheum 19: 629-636, 1976
 
29) Staalman CR, Umans U: Hypertrophic osteoarthropaty in childhood malignancy. Med Pediatr Oncol 21: 676-679, 1993
PubMed
30) Goldberg E, Dobransky R, Gill R: Reflex sympathetic dystrophy associated with malignancy. Arthritis Rheum 28: 1079-1080, 1985
PubMed
31) Medsger TA, Dixon JA, Garwood VF: Palmar fascitis and polyarthritis associated with ovarian carcinoma. Ann Intern Med 96: 424-431, 1982
PubMed
32) Shiel WC, Prete PE, Jason M, et al: Palmar fasciitis and arthritis with ovarian and non-ovarian carcinomas; New syndrome. Am J Med 79: 640-644, 1985
PubMed
33) Champion D, Saxon JA, Kossard S: The syndrome of palmar fibromatosis (fasciitis) and polyarthritis. J Rheumatol 14: 1196-1198, 1987
 
34) Lambert CM, Nuki G: Multicentric reticulohistiocytosis with arthritis and cardiac Infiltration; Regression following treatment for underlying malignancy. Ann Rheum Dis 51: 815-817, 1992
PubMed
35) Rapini RP: Multicentric reticulohistiocytosis. Clin Dermatol 11: 107-111, 1993
PubMed
P.64 掲載の参考文献
1) 松井好人, 木村友厚, 安井夏生:解明された骨系統疾患と原因遺伝子の対応. 細胞工学17: 363-371, 1988
 
2) International Working Group on Constitutional Disease of Bone: International nomenclature and classification of the osteochondro dysplasia (1997). Am J Med Gen 79: 376-382, 1998
 
3) 鬼頭浩史, 野上宏: 骨系統疾患のFGFR (fibroblast growth factor receptor) の変異. 小児内科30: 398-402, 1998
 
4) Weiss MJ, Cole DEC, Ray K, et al: Amissence mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia. Proc Natl Acad Sci USA 85: 7666-7669, 1988
 
5) Ozono K, Yamagata M, Michigami T, et al: Identification of novel missense mutations (Phe310Leu and Gly439ARG) in a neonatal case of hypophosphatasia. J Clin End Metab 81: 4458-4461, 1996
 
6) 安井夏生: コラーゲンの変異遺伝子. 小児内科30: 403-408, 1998
 
7) Maroteaux P, Lamy M: The malady of Toulouse. Lautrec. JAMA 191: 715-717, 1965
PubMed
8) Gelb BD, Edelson JG, Desnick RL: Linkage of pycnodysostosis to 1q21 by homozygozity mapping. Nature Genetics 10: 235-237, 1995
 
9) Polymeropoulos MH, Ortiz De Luna RI, Ide SE, et al: The gene for pycnodysostosis maps to human chromosome 1q21. Nature Genet 10: 238-239, 1995
 
10) Gelb BD, Shi GP, Chapman HA, et al: Pycnodysostosis, a lysozomal disease caused by cathepsin K deficiency. Science 273: 1236-1238, 1996
 
11) Saftig P, Hunzinger E, Wehmeyer O, et al: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc Natl Acad Sci USA 95: 13453-13458, 1998
 
12) Gowen M, Lazner F, Dodds R, et al: Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14: 1654-1663, 1999
 
P.75 掲載の参考文献
1) Gejyo F, et al: A new form of amyloid protein associated with chronic bemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 129: 701-706, 1985
 
2) 楊鴻生: 透析関節症の病理組織.MB Orthop 9: 33-39, 1996
 
3) Kuntz D, Naveau B, Bardin T, et al: Destructive spondylarthropathy in hemodialyzed patients. A new syndrome. Arthritis Rheum 27: 369-375, 1984
PubMed
4) 圓尾宗司, 松本學, 谷口睦ら: 長期透析患者における脊椎病変 (DSA). 日脊会誌8: 317-329, 1997
 
5) Allain TJ, Stevens PE, Bridges LR, et al: Dialysis myclopathy; quadriparesis due to extradural amylod of β2 microglobulin origin. Br Med J 296: 752-753, 1988
 
6) 久野木順一, 真光雄一-郎, 赤津昇ら: 長期透析患者の腰部脊柱管狭窄症における黄色靱帯肥厚の意義. 日脊会誌8: 62, 1997
 
7) 圓尾宗司, 楊鴻生: 長期透析患者にみられるDestructive Spondyloarthropathyの診断と治療. Orthop 30: 99-105, 1990
 
8) 圓尾宗司, 松本學: 破壊性脊椎関節症の手術的治療. MB Orthop 9: 9-16, 1996
 
9) Rousselin B, Helenton O, Zingraff et al: Pseudotummor of the craniocervical junction during long-term hemodyalysis. Arthritis Rheum 33: 1567-1573, 1990
 
10) 谷口睦, 圓尾宗司: DSA脊椎の外科治療. 透析患者の合併症とその対策. 骨.関節障害, 日本透析医学会: 51-62, 1996
 
11) 谷澤龍彦, 高橋英明, 山田智晃ら: 長期透析患者と整形外科, 脊椎病変. 整・災外39: 219-225, 1996
 
P.84 掲載の参考文献
1) Bernard TN, Kirkaldy-Willis WH: Recognizing specific characteristics of non specific low back pain. Clin Orthop 217: 266-280, 1985
 
2) Chisin R, Milgrom C, Margulies J, et al: Unilateral sacroiliac overuse syndrome in military recruits. Br Med J 289: 590-591, 1984
 
3) Marymont JV, Lynch MA, Henning CE: Exercise-related stress reaction of sacroiliac joint; An unusual cause of lowback pain in athletes. Am J Sport Med 14: 320-323, 1986
 
4) 大場俊二: 本邦老人仙腸関節の形態学的研究およびその関節軟骨面の肉眼的組織学的観察. 日整会誌59: 675-689, 1985
 
5) 三浦啓志: 仙腸関節の生力学的特性. 日整会誌61: 1093-1105, 1987
 
6) 仲川富雄: 日本人仙腸関節および近接域の神経細末の分布に関する研究. 日整会誌,40: 419-430, 1966
Medical*Online
7) Cibulka MT, Koldehoff R: Clinical usefulness of a cluster of sacroiliac joint tests in patients with and without low back pain. J Orthop Sports Phys Ther 29: 83-92, 1999
PubMed
8) Schwarzer AC, April CN, Bogduk N, et al: The sacroiliac joint in chronic low back pain. Spine 20: 31-37, 1995
 
9) Dreyfuss P, Michaelsen M, Pauza K, et al: The value of medical history and physical examination in diagnosing sacroiliac joint pain. Spine 21: 2594-2602, 1996
PubMed
10) Ebraheim NA, Xu R, Nadaud M, et al: Sacroiliac joint injection: acadaveric study. Am J Orthop 23: 338-341, 1997
 
11) 村上栄一, 石塚正人, 渡辺一弘: 仙腸関節性疼痛の発痛部位のブロックによる検索. 整・災外41: 1293-1298, 1998
 
12) Luukkainen R, Nissila M, Asikainen E, et al: Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 17: 88-90, 1999
PubMed
13) 山元功, Panjabi MM: 仙腸関節の三次元動態解析. 関節外科18: 500-504, 1999
 
14) Kissling RO, Jacob HAC: The mobility of the sacroiliac joint in healthy subjects. Bull Hospital Joint Dis 54: 158-164, 1996
 
15) Battistone MJ, Manaster BJ, Reda DJ, et al: Radiographic diagnosis of sacroiliitis; Are sacroiliac views really better? J Rheumatol 25: 2395-2401, 1998
 
16) Prassopoulos PK, Faflia CP, Voloudaki AE, et al: Sacroiliac joints: A natornical variants on CT. J Comput Assist Tomogr 23: 323-327, 1999
PubMed
17) Yu W, Feng F, Dion E, et al: Comparison of radiography, computed tomography and magnetic resonance imaging in the detection of sacroiliitis accompanying ankylosing spondylitis. Skeletal Radiol 27: 311-320, 1998
PubMed
18) Dunn EC, Ebringer RW, Ell PJ: Quantitative scintigraphy in the early diagnosis of sacroiliitis. Rheumatol Rehabil 19: 69-75, 1980
 
19) Ailsby RL, Staheli LT: Pyogenic infections of the sacroiliac joint in children. Radioisotope bone scanning as a diagnostic tool. Clin Orthop 100: 96-100, 1974
PubMed
20) Jajic I, Jajic Z: The prevalence of osteoarthrosis of the sacroiliac joints in an urban population. Clin Rheumatol 6: 39-41, 1987
 
21) 白井康正: 仙腸関節の画像診断-骨盤骨折と仙腸関節-, 関節外科18: 506-511, 1999
 
22) Faflia CP, Prassopoulos PK, Daskalogiannaki ME, et al: Variation in the appearance of the normal sacroiliac joint on pelvic CT. Clin Radiol 53: 742-746, 1998
PubMed
23) Stewart TD: Pathologic changes in aging sacroiliac joints. A study of dissectingroom skeletons. Clin Orthop 183: 188-196, 1984
PubMed
24) Russel AS, Lentle BC, Percy JS: Investigation of sacroiliac disease; Comparative evaluation of radiological and radionuclide techniques. J Rheumatol 2: 45-51, 1975
 
25) Goldberg RP, Genant HK, Shimsak R, et al: Applications and limitations of quantitative sacroiliac joint scintigraphy. Radiology 128: 683-686, 1978
 
26) Rendich RA: Osteitis condensans ilii. J Bone Joint Surg 18: 899-908, 1936
 
27) Schwarzer AC, Aprill CN, Bogduk N: The sacroiliac joint in chronic low back pain. Spine 20: 31-37, 1995
PubMed
28) Maigne JY, Boulahdour H, Chatellier G: Value of quantitative radionuclide bone scanning in the di-agnosis of sacroiliac joint syndrome in 32 patients with low back pain, Eur Spine J 7: 328-331, 1998
 
29) 七川歡次, 辻本正記, 小瀬弘一ら: 強直性脊椎炎-その早期診断頻度, 病因について. リウマチ病II, 七川歡次編, p188, 大阪, 永井書店, 1973
 
30) Bowen V, Cassidy JD: Macroscopic and microscopic anatomy of the sacroiliac joint from embryonic life until the eighth decade. Spine 6: 620-628, 1981
PubMed
31) Walker JM: Age-related differences in the human sacroiliac joint; A histological study; Implications for therapy. J Orthop Sports Phys Ther 7: 325-334, 1986
PubMed
32) Kampen WU, Tillmann B: Age-related changes in the articular cartilage of human sacroiliac joint. Anat Embryol 198: 505-513, 1998
PubMed
33) 七川歓次: 強直性脊椎炎. リウマチ16: 395-407, 1976
 
P.94 掲載の参考文献
1) Lichtman M, Komp D: Inflammatory and malignant histiocytosis. In: Williams Hematology, 5th ed (Ed, Beutler E, et al), pp885-894, New York, McGraw-Hill, Inc, 1998
 
2) Cline MJ: Histiocytes and histiocytosis. Blood 84: 2840-2853, 1994
PubMed
3) Nicholson S, Lukens JN: Langerhans cell histiocytosis. In: Wintrobe's clinical hematology, 10th ed (Ed, Lee R et al), pp1916-1925, Baltimore, Williams & Wilkins, 1999
 
4) Lipton J: Histiocytic syndromes. In: Hematology, 2nd ed (ed, Hoffman R, et al), pp838-851, New York, Churchill Livingstone, 1995
 
5) The Writing Group of th Histiocyte Society: Histiocytosis syndromes in children, Lancet 1: 208-209, 1987
 
6) Liebermann PH, Jones CR, Steinman RM, et al: Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol 20: 519-552, 1996
 
7) Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al: Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine 75: 157-169, 1996
PubMed
8) Tazi A, Emile J-F, Soler P, et al: Histiocytoses. In: Maladies et Syndromes Systemiques (Ed, Kahn M-F, Peltier A-P, Meyer O, et al), pp1077-1098, Paris, Flammarion, 2000
 
9) Nezelof C, Basset F: Langerhans cell histiocytosis research. Past, present and future. Hematol Oncol Clin North Am 12: 385-406, 1998
PubMed
10) Schulitz KP, Niggemeyer O: Historical perspective. Jacques Calve. Spine 21: 886-890, 1996
 
11) Siegelman SS: Taking the X out of histiocytosis X. Radiology 204: 322-324, 1997
PubMed
12) Willman L, Busque L, Griffith BB, et al: Langerhans'-cell histiocytosis (histiocytosis X)-A clonal proliferative disease. N Engl J Med 331: 154-160, 1994
 
13) 日本整形外科学会骨軟部腫瘍委員会編: 全国骨腫瘍患者登録一覧表: 国立がんセンター, 1994
 
14) Kilpatrick SE, Wenger DE, Gilchrist GS, et al: Langerhans: cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer 76: 2471-2484, 1995
 
15) Howorth DM, Gilchrist GS, Mu}lan BP, et al: Langerhans cell histiocytosis. Diagnosis, natural history, management and outcome. Cancer 85: 2278-2290, 1999
 
16) Travis WD, Brook Z, Roum JH, et al: Pulmonary Langerhans cell granulomatosis (Histiocytosis X). A clinicopathological study of 48 cases. Am J Surg Pathol 17: 971-986, 1993
 
17) Youkeles LH, Grizzanti JN, Liao Z, et al: Decreased tobacco-glycoprotein-induced lymphocyte proliferation in vitro in pulmonary eosinophilic granuloma. Am J Respir Crit Care Med 151: 145-150, 1995
PubMed
P.101 掲載の参考文献
1) Goldstein JL, Hobbs HH, Brown MS: Familial Hypercholesterolemia. In: The Metabolic and Molecular Bases of Inherited Disease (Eds, Scriver CR, et al), pp1981-2030, NY, McGraw-Hill, Inc.
 
2) 原発性高脂血症の分類と診断基準 厚生省特定疾患原発性高脂血症調査研究班昭和62年度研究報告書 (垂井清一郎班長) pp26-34, 1988
 
3) Wysenbeek AJ, Shani E, Beigei Y: Musculoskeletal Manifestations in Patients with Hypercholesterolemia. J Rheumatol 16: 643-645, 1989
 
4) Mathon G, Gagne C, Brun D, et al: Articular Manifestations of Familial Hypercholesterolemia. Ann Rheum Dis 44: 599-602, 1985
PubMed

燐・カルシウム代謝

P.110 掲載の参考文献
1) 川口浩: 性ステロイド. 最新骨粗鬆症 (折茂肇編集), pp186-190, 東京, ライフサイエンス出版, 1999
 
2) Komm BS, Terpening CM, Benz DJ, et al: Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 241: 81-84, 1988
PubMed
3) Ernst M, Heath JK, Rodan GA, et al: Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-1, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. Endocrinology 125: 825-833, 1989
PubMed
4) Oursler MJ, Osdoby P, Pyfferoen J, et al: Avian osteoclasts as estrogen target cells. Proc Natl Acad Sci USA 88: 6613-6617, 1991
PubMed
5) Pacifici R, Rifas L, McCracken R, et al: 0varian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin l release. Proc Natl Acad Sci USA 86: 2398-2402, 1989
 
6) Pacifici R, Brown C, Puscheck E, et al: Effects of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci USA 88: 5134-5138, 1991
PubMed
7) Girasole G, Jilka RL, Passeri G, et al: 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro; Apotential mechanism for the antio-steoporotic effect of estrogens. J Clin Invest 89: 883-891, 1992
 
8) Christiansen C, Christensen MS, Transbol I: Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 28: 459-461, 1981
 
9) Lindsay R, Tohme JF: Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 76: 290-295, 1990
PubMed
10) 森井浩世: Tissue selective estrogenの臨床評価. 骨粗鬆症財団主催第18回教育ゼミナール講演会記録, pp 8-14, 東京, ライフサイエンス出版, 1997
 
11) Grady D, Rubin SM, Petitti DB, et al: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117: 1016-1037, 1992
PubMed
12) 中山昌樹, 五来逸雄: エストロゲンアンタゴニスト・アゴニストによる治療. CLINICAL CALCIUM 5: 502-505, 1995
 
13) Ryan PJ, Harrison R, Blake GM, et al: Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis, Br J Obstet Gynaecol 99: 325-328, 1992
PubMed
14) Kauffman RF, Bryant HA: Selective estrogen receptor modulators Drug News and Perspectives 8: 531-539, 1995
 
15) Yang NN, Bryant HU, 中澤隆弘: ラロキシフェンの組織特異的作用の分子機構.Molecular Medicine 35: 520-526, 1998
 
16) Kuiper GGJM, Enmark E, Pelto-Huikko M, et al: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925-5930, 1996
 
17) Mosselman S, Polman J, Dijkema R: ER β: identification and characterization of a novel human estrogen receptor. FEBS Lett 392: 49-53, 1996
 
18) Grese TA, Sluka JP, Bryant HU, et al: Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94: 14105-14110, 1997
PubMed
19) Inoue S, Orimo A, Hosoi T, et al: Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci USA 90: 11117-11121, 1993
PubMed
20) Webb P, Lopez GN, Uht RM, et al: Tamoxifen activation of the estrogen receptor/AP-1 pathway; Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9: 443-456, 1995
 
21) Shibata H, Spencer TE, Onate SA, et al: Role of co-activators and corepressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 52: 141-165, 1997
PubMed
22) Wehling M: Nongenomic actions of steroid hormones. Trends Endocrinol Metab 5: 347-353, 1994
PubMed
23) Yang NN, Bryant HU, Hardikar S, et al: Estrogen and raloxifene stimulate transforming growth factor-β3 gene expression in rat bone; Apotential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 137: 2075-2084, 1996
 
24) Draper MW, Flowers DE, Huster WJ, et al: A controlled trial of raloxifene (LY139481) HC1: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11: 835-842, 1996
 
25) Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647, 1997
 
26) Lufkin EG, Whitaker MD, Nickelsen T, et al: Treatment of established postmenopausal osteoporosis with raloxifene; Arandomized trial. J Bone Miner Res 13: 1747-1754, 1998
 
27) Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 282: 637-645, 1999
PubMed
28) Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281: 2189-2197, 1999
PubMed
29) Shughrue PJ, Scrimo PJ, Merchenthaler I: Estrogen binding and estrogen receptor characterization (ER α and ER β) in the cholinergic neurons of the rat basal forebrain. Neuroscience 96: 41-49, 2000
 
30) Ushiyama T, Ueyama H, Inoue K, et al: Expression of genes for estrogen receptors α and β in human articular chondrocytes. Osteoarthritis Cart 7: 560-566, 1999
 
31) Wu X, Glinn MA, Ostrowski NL, et al: Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res 847: 98-104, 1999
PubMed
32) Dequeker J: The relationship between osteoporosis and osteoarthritis. Clin Rheum Dis 11: 271-296 1985
PubMed
P.120 掲載の参考文献
1) Murer H, Wermer A, Reshkin S, et al: Cellular mechanisms in proximal tubular reabsorption of inorganic phosphate. Am J Physiol 260: C885-C899, 1991
 
2) Werner A, Moore ML, Mantel N, et al: Cloning and expression of cDNA for a Na/pi cotransportsystem of kidney cortex. Proc Natl Acad Sci USA 88: 9608-9612, 1991
 
3) Magagnin S, Werner A, Markovich D, et al: Expression cloning of human and rat renal cortex. Na/Pi cotransport. Proc Natl Acad Sci USA 90: 5979-5983, 1993
 
4) Verri T, Markovich D, Perego C, et al: Cloning and regulation of a rabbit renal Na/Picotransporter. Am J Physiol 286: F626-633, 1995
 
5) Stephen A, Kempson SA, Letscher M, et al: Parathyroid hormone action on phoshate transporter mRNA and protein in rat renal proximal tubules. Am J Physiol 268: F784-791, 1995
 
6) Lotscher M, Kaissling B, Biber J, et al: Regulation of rat renal Na/Pi cotransporter by parathyroihormone; Immunohistochemistry. Kidney Int 49: 1010-1011, 1996
 
7) Hamsch E, Forgi J, Murer H, et al: Role of microtubules in the adaptive response to low phosphate of Na/Pi cotransporter. in opossum kidney cells. Pfugers Arch 422: 516-522, 1993
 
8) Levi M, Lotscher M, Sorribas V, et al: Cellular mechanisms of acute and chronic adaptation of ratrenal Pi transporter to atterations in dietary Pi. Am J Physiol 267: F900-F908, 1994
 
9) Loghman-Adham M: Adaptation to changes in dietary phosphorus intake in health and in renalfailure. J Lab Clin Med 129: 176-188, 1997
 
10) Katai K, Segawa H, Haga H, et al: Acute regulation by dietary phosphate of the sodium-dependent phosphate transporter (NaPi-2) in rat kidney. J Biochem 121: 50-55, 1997
 
11) Econs MJ, Drezner MK: Tumor-induced osteomalacia-unveiling a new hormone. N Engl J Med 330: 1679-1681, 1994
PubMed
12) Baylink D, Wergedal J, Staufter M: Formation, mineralization and resorption of bone in hypophosphatemic rats. J Clin Invest 50: 2519-2530, 1971
 
13) Thompson E, Baylink D, Wergedal J: Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in the rat. Endocrinology 97: 283-289, 1975
PubMed
14) Bruin WJ, Baylink DJ, Wergedal JE: Acute inhibition of mineralization and stimulation of boneresorption mediated by hypophosphatemia. Endocrinology 96: 394-399, 1975
 
15) Ecarot B, Glorieux FH, Desbarats M, et al: Effect of dietary phosphate deprivation and supplementation of recipient mice on bone formation by transplanted cells from normal and X-linked hypophosphatemic Mice. J Bone Miner Res 7: 523-530, 1992
 
16) Harris WH, Heaney RP, Davis LA, et al: Stimulation of bone formation in vivio by phosphate supplementation. Calcif Tissue Res 22: 85-98, 1976
 
17) De Vernejoul MC, Marie P, Kuntz D, et al: Nonosteomalacic osteopathy associated with chronichypophosphatemia. Calcif Tissue Int 34: 219-233, 1982
PubMed
18) Laroche M, Arlet J, Ader JI., et al: Skelltal manifestation of moderate phosphate diabetes. Clin Rheum 12: 192-197, 1993
 
19) Cuisinier-Gleizes P, Thomasset M, Sainteny-Debove F, et al: Phosphorus deficiency, parathyroidhormone and bone resorption in the growing rat. Calcif Tissue Res 20: 235-240, 1976
 
20) Bingham PJ, Raisz LG: Bone growth in organ culture; Effects of phosphate and other nutrients onbone nd cartilage. Calcif Tissue Res 14: 31-48, 1974
 
21) Asher MA, Sledge CB, Glimcher MJ, et al: The effect of inorganic orthophosphate on the rates of collagen formation and degradation in bone and cartilage in tissue culture. J Clin Endocrinol Metab 38: 376-389, 1974
PubMed
22) Raisz LG: Bone formation and resorption in tissue culture; Effect of agents implicated in renalosteodystrophy. Arch Intern Med 126: 887-889, 1970
 
23) Yates AJ, Orefto ROC, Mayor K, et al: Inhibition of bone resorption by inorganic phosphate is mediated by both reduced osteoclast formation and decreased activity of mature osteoclasts. J Bone Miner Res 6: 473-479, 1991
 
24) Tatsumi S, Segawa H, Morita K, et al: Molecular cloning and hormonal regulation of PiT-1, a sodium-dependent phosphate cotransporter from rat parathyroid glands. Endocrinology 139: 1692-1699, 1998
PubMed
25) Gupta A, Guo XL, Alvarez UM, et al: Regulation of sodium-dependent phosphate transporter in osteoclasts. J Clin Invest 100: 538-549, 1997
PubMed
26) HYP Consortium: Agene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11: 130-136, 1995
 
27) Nelson AE: The PEX gene: Not a simple answer for X-linked hypophosphatemic rickets and oncogenic osteomalacia Mol Cell Endocrinol 132: 1-5, 1997
 
28) Drezner MK: Tumor-induced rickets and osteomalacia. Favus MJ (ed); Primer on the metabolic bone diseases and disorders of mineral metabolism, 3rd ed, pp319-325, Lippincott-Raven, Philadelphia, 1996
 
29) Tenenhouse HS, Jones G: Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine models for X-linked hypophosphatemic rickets. J Clin Invest 85: 1450-1455, 1990
 
30) Miyauchi A, Fukase M, Tsutsumi M, et al: Hemangiopericytoma induced osteomalacia; Tumor transplantation in nude mice canses hypophosphatemia and tumor extracts inhibit renal 25-hydroxy-vitamin D1-hydroxylase activity, J Clin Endocrinol Metab 67: 46-53, 1988
 
31) Yanagawa N, Nakhoul F, Kurokawa K: Physiology of phosphorus metabolism. Narins RG (ed), Clinical Disorders of Fluid and Electrolyte Metabolism, McGraw-Hill 5th, pp344-350, New York, 1995
 
32) Travis SJ, Sugerman HJ, Ruberg RL, et al: Alterations of red cell glycolytic intermediates and oxygen transport as a consequence of hypophosphatema in patients receiving intravenous hyper. alimentation. N Engl J Med 285: 763-768, 1971
 
33) Craddock PR, Yawata Y, Van Santen L, et al: Acquired phagocyte dysfunction; A complication of the hypophosphatemia of parenteral hyperalimentation. N Engl J Med 290: 1403-1407, 1974
PubMed
34) Yawata Y, Hebbel RP, Silvis S, et al: Blood cell abnormalities complicating the hypophosphatemia of hyperalimentation; Erythrocyte and platelet ATP deficinency associated with hemolytic anemia and bleeding in hyperalimented dogs. J Lab Clin Med 84: 643-653, 1974
 
35) Weintraub M: Hypophosphatema mimicking acute Guillain-Barre-Strohl syndrome; A complication of parenteral hyperalimentation. JAMA 235: 1040-1041, 1976
 
36) Knochel JP, Barcenas C, Cotton JR, et al: Hypophosphatemia and rhabdomyolysis. J Clin Invest 62: 1240-1246, 1978
PubMed
37) O'Connor LR, Wheeler WS, Bethune JE: Effect of hypophosphatemia on myocardical performance in man. N Engl J Med 291: 901-913, 1977
 
38) Rent CE, Stamp TCB: Hypophosphatemic osteomalacia presenting in adults. Q J Med 40: 303-329, 1971
 
39) Laroche M, Moulinier E, Bon E, et al: Renal tubular disorders and arteriopathy of the lower limbs; Risk factors for osteoporosis in men? Osteoporosis Int 4: 309-313, 1994
 
40) Moser CR, Fessel WJ: Rheumatic manifestations of hypophosphatemia. Arch Intern Med 134: 674-678, 1974
PubMed
41) Amor B: Manifestations osteo-articulaires du diabete phosphore mineur de l'adulte. Proceeding of 15th International Congress of Rheumatology, Hopital Cochin, Phosphore et maladies de l'appareil locomoteur, 1999
 
P.133 掲載の参考文献
1) Slemenda CW, Christian JC, Williams CJ, et al: Genetic determinants of bone mass in adult women; A re evaluation of the twin model and the potential importance of gene interaction on heritability estimates. J Bone Miner Res 6: 561-567, 1991
 
2) Morrison NA, Yeoman R, Kelly PJ, et al: Contribution of trans-acting factor alleles to normal physiological variability; Vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Natl Acad Sci USA 89: 6665-6669, 1992
PubMed
3) 橋本淳: ビタミンDレセプター. リウマチ病セミナーIX (七川歡次監修), pp161-168, 大阪, 永井書店, 1998
 
4) Dempster DW, Lindsay R: Pathogenesis of osteoporosis. Lancet 341: 797-801, 1993
PubMed
5) Smith DM, Nance KW, Kang JC, et al: Genetic factors in determining bone mass. J Clin Invest 52: 2800-2808, 1973
 
6) Pocock NA, Eisman JA, Hopper JL, et al: Genetic determinants of bone mass in adults. A twin study. J Clin Invest 80: 706-.710, 1987
 
7) Morrison NA, Qi Jc, Tokita A, et al: Prediction of bone density from vitamin D receptor alleles. Nature 367: 284-287, 1994
PubMed
8) Tokita A, Matsumoto H, Morrison NA, et al: Vitamin D receptor alles, bone mineral density and turnover inn premenopausal Japanese women. J Bone Miner Res 11: 1003-1009, 1996
 
9) Yamagata Z, Miyamura T, Iijima S, et al: Vitamin D receptor gene polymorphisms and bone mineral density inn healthy Japanese women. Lancet 344: 1027, 1994
 
10) Matsuyama T, Ishii S, Tokita A, et al: Vitamin D receptor genotypes and bone mineral density Lancet 345: 1238-1239, 1995
PubMed
11) Kiel D, Myers RH, Cupples LA, et al: The Bsm I vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density. J Bone Miner Res 12: 1049-1057, 1997
 
12) Ferrari SL, Rizzoli R, Cheralley T, et al: Vitamin D gene polymorphisms and the rate of change of lumbar spine bone mineral density in the elderly. Lancet 345: 423-424, 1995
 
13) Dawson-Hughes B, Harris SS, FInneran S: Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. JCE & M 80: 3657-3660, 1995
 
14) 宮本賢一, 新井英一: 骨量を規定する遺伝子. Medicine 35: 1088-1090, 1998
 
15) Garnero P, Borel O, Sornay-Rendu E, Arlot ME, et al: Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women; The OFELY study, J Bone Miner Res 11: 827-834, 1996
 
16) 井上聡: エストロゲン受容体遺伝子多型. 最新骨粗鬆症, 病態, 診断, 予防, 治療 (折茂肇編), pp386-393, 東京, ライフサイエンス, 1999
 
17) 山縣然太朗: エストロゲンレセプター遺伝子と骨代謝. 医学のあゆみ186: 899-903, 1998
 
18) Kobayashi S, Inoue S, Hosoi T, et al: Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 11: 306-311, 1996
 
19) 水沼英樹: エストロゲン受容体遺伝了.多型から何が分かるか. Osteoporosis Japan 6: 189-193, 1998
 
20) Sano M, Inoue S, Hosoi T, et al: Association of estrogen receptor dinucleotide repeat polymorphism with osteoporosis. Biochem Biophys Res Commun 217: 378-383, 1995
PubMed
21) Shiraki M, Shiraki Y, Aoki C, et al: Association of bone mineral density with a polypoprotein E phenotype. J Bone Miner Res 12: 1438-1445, 1997
PubMed
22) Eto M, Watanabe K, Ishii K, et al: Racial difference in apolipopurotein E allele frequencies between the Japanese and Caucasian populations. Clin Genet 30: 422-427, 1986
PubMed
23) 細井孝之: 副甲状腺ホルモン, カルシトニン遺伝子多型と骨粗鬆症. Oseoporosis Japan 6: 199-202, 1998
 
24) Masi L, Becherini L, Colli E, et al: Polyorphisms of the calcitonin receptor gene are associated with bone mineral dencity in postmenopausal italian women. Biochem Biophysical Resear communications 248: 190-195, 1998
 
25) Uitterlinden AG, Burger H, Huang Q, et al: Relation of alleles of the collagen type IaI gene to bone density and the risk of osteoporotic fractures in postmenopausal women. N Engl Med 210: 554-558, 1989
 
26) Langdahl B, Ralson S, Grant SFA, et al: An Sp1 binding site polymorphism in the COLIAI gene predicts osteoporotic fractures in both men and women. J Bone Miner Res 13: 1384-1389, 1998
 
27) Murray RE, McGuigan F, Grant SF, et al: Polymorphisms of the interleukin-6 gene are associated with bone mineral density. Bone 21: 89-92, 1997
PubMed
28) Yamada Y, Miyauchi A, Goto J, et al: Association of a polymorphism of the transforming growth factor-beta gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 13: 1569-1576, 1998
PubMed
29) Miyao M, Hosoi T, Inoue S, et al: Polymorphism of insulin-like growth factor I gene and bone mineral density. Calcif Tissue Int 63: 306-311, 1998
PubMed
30) Dohi Y, Iki M, Ohgushi H, et al: Anovel polymorphism in the promoter region for the human osteocalcine gene; The possibility of a correlation with bone mineral density in post monopausal Japanese women. J Bone Miner Res 13: 1633-1639, 1998
 

検査法

P.141 掲載の参考文献
1) 中田力: MRの基礎. 「脳脊髄MRA」-基礎と臨床, 流れの画像化 (中田力, 宝金清博編) pp1-24, 東京, 中外医学社, 1997
 
2) 宝金清博:脳動脈瘤のMRA. 「脳脊髄MRA」-基礎と臨床, 流れの画像化-(中田力, 宝金清博編) pp 55-83, 東京, 中外医学社, 1997
 
3) 青樹毅: 閉塞性脳血管病変のMRA, 「脳脊髄MRA」-基礎と臨床, 流れの画像化, 中田力, 宝金清博編, pp86-104, 東京, 中外医学社, 1997
 
4) Schwartz RB, Tice HM, Hooten SM, et al: Evaluation of cerebral aneurysms with helical CT: correlation with conventional angiography and MR angiography. Radiology 192: 717-722, 1994
 
5) 宝金清博: 頸部血管のMRA.「脳脊髄MRA」-基礎と臨床, 流れの画像化-(中田力, 宝金清博編) pp 137-151, 東京, 中外医学社, 1997
 
6) 隅田昌之, 井川房夫, 魚住徹: Phase contrast法の臨床応用. 「脳脊髄MRA」-基礎と臨床, 流れの画像化-(中田力, 宝金清博編) pp151-168, 東京, 中外医学社, 1997
 
7) 青樹毅: 脳血管奇形のMRA. 「脳脊髄MRA」-基礎と臨床, 流れの画像化-(中田力, 宝金清博編) pp106-117, 東京, 中外医学社, 1997
 
8) 吉岡邦浩, 玉川芳春: 脈管疾患の非侵襲的画像診断法-大動脈疾患MRA, 臨床画像13: 912-919, 1997
 

生物学的反応

P.154 掲載の参考文献
1) Peakman M, Vergani D: 自然免疫I. 物理的および体液性防衛. 免疫学-主要疾患発症のメカニズム, 湊長博訳, pp9-20, 東京, メディカルサイエンスインターナショナル, 1999
 
2) Abbas AK, Lichtman AH, Pober JS: The Complement System. Cellular and Molecular Immunology, pp259-282, Philadelphia, W. B. Saunders Company, 1991
 
3) 中村宣雄, 木下タロウ: 補体とその異常. 免疫のしくみと疾患 (平野俊夫編), pp74-78, 東京, 羊土社, 1997
 
4) 竹村周平: 補体価, C3, C4. 臨床検査ガイド (和田攻, 大久保昭行, 永田直一ら編), pp1999-2000, 東京, 文光堂, 1999
 
P.165 掲載の参考文献
1) Risch N: Linkage strategies for genetically complex traits. III. The effect of marker polymorphism on analysis of affected relative paire. Am J Hum Genet 46: 242-253, 1990
 
2) Holmans P: Asymptotic properties of affected-sib-pair linkage analysis. Am J Hum Genet 52: 362-374, 1993
PubMed
3) Davies JL, Kawaguchi Y, Bennett ST, et al: Agenome-wide search for human type 1 diabetes susceptibility genes. Nature 371: 130-136, 1994
 
4) Holmans P, Clayton D: Efficiency of typing unaffected relatives in an affected-sib-pair linkage study with single-locus and multiple tightly linked markers. Am J Hum Genet 37: 1221-1232, 1995
 
5) Shiozawa S, Hayashi S, Tsukamoto Y, et al: Identification of the gene that predispose to rheumatoid arthritis. Int. Immunol 10: 1891-1895, 1998
PubMed
6) Konishi Y, Mukae N, Sato M, et al: DR3 (death receptor 3) gene as rheumatoid arthritis disease gene 1. (In preparation)
 
7) Komai K, Hikasa M, Yamatomo E, et al: Db1 protooncogene as rheumatoid arthritis disease gene 3. (In preparation)
 
P.171 掲載の参考文献
1) Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (61) 229: 524-526, 1987
 
2) Farrell AJ, Blake DR, Palmer RM, et al: Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic disease. Ann Rheum Dis 51: 1219-1222, 1992
PubMed
3) Melchiorri C, Meliconi R, Frizziero L, et al: Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 41: 2165-2174, 1998
PubMed
4) Amin AR, Abramson SB: The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 10: 263-268, 1998
PubMed
5) McCartney FN, Allen JB, Mizel DE, et al: Suppression of arthritis by an inhibition of nitric oxide synthase. J Exp Med 178: 749-754, 1993
 
6) Weinberg JB, Granger DL, Pisetsky DS, et al: The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-1pr/1pr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administrated NG-monomethyl-L-arginine. J Exp Med 179 (2): 651-660, 1994
 
7) Sakurai H, Kohsaka H, Liu MF, et al: Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritis. J Clin Invest 96: 2357-2363, 1995
PubMed
8) Amin AR, Vyas P, Attur MG, et al: The mode of action of aspirin-1ike drugs: effect on inducible nitric oxide synthase. Proc Natl Acad Sci USA 92: 7926-7930, 1995
 
9) Amin AR, Attur MG, Thakker GD, et al: A novel mechanism of action of tetracyclines: effect on nitric oxide synthase. Proc Natl Acad Sci USA 93: 14114-14019, 1996
 
10) Perkins DJ, St Misukonis MA, Weinberg JB: Reduction of NOS2 Overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum 41: 2205-2210, 1998
 
11) Miyasaka N, Hirata Y, Ando K, et al: Increased production of endothelin-1 in patients with inflammatory arthritides. Arthritis Rheum 35: 397-400, 1992
PubMed
12) Stichtenoth DO, Wollenpauth J, Anderson D, et al: Elevated serum nitrate concentrations in active spondylarthropathies. Br J Rheumatol 34: 616-619, 1995
 
13) Aiko S, Grisharm MB: Spontaneous intestinal inflammation and nitric oxide metaboism in HLA-B27 transgenic rats. Gastroenterology 109: 142-150, 1995
 
P.180 掲載の参考文献
1) Buckwalter J, Rosenberg L, Coutts R, et al: Articular cartilage: injury and repair. In: Injury and repair of the musculoskeletal soft tissues (Eds, Buchwalter J, Woo SLY), pp465-482, Park Ridge, Illinois, The American Academy of Orthopaedic Surgeons, 1987
 
2) Mitchell N, Shepard N: The resurfacing of adult rabbit articular cartilage by multiple perforations through the subchorldral bone. J Bone Joint Surg 58. A: 230-233, 1976
 
3) Matsusue Y, Yamamura T, Hama H: Arthroscopic multiple osteochondral transplantation to thechondral defect in the knee associated with anterior cruciate ligament disruption. Arthroscopy 9: 318-321, 1993
 
4) Brittberg M, Lindahl A, Nilsson A, et al: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. New England J Med 331: 889, 1994
 
5) Aston JE, Bentley G: Repair of articular surfaces by allografts of articular and growth-plate cartilage. J Bone Joint Surg 68-B: 29-35, 1986
 
6) Kimura T, Yasui N, Ohsawa S, et al: Chondrocytes embedded inn collagen gels maintain cartilagephenotype during long-term cultures. Clin Orthop Rel Res 186: 231-239, 1984
 
7) Wakitani S, Kimura T, Hirooka A, et al: Repair of rabbit articular surfaces with allograft chondrocytes embedded in collagen gel. J Bone Joint Surg 71-B: 74-80, 1989
 
8) Wakitani S, Goto T, Young RG, et al: Repair of large full-thickness articular cartilage defects with allograft articular chondrocytes embedded in a collagen gel. Tissue Engin 4: 429-444, 1998
 
9) Kawamura A, Wakitani S, Maeda A, et al: Cartilage repair; A collagen gel-biomatrix hardenedby chondrocytes cultured within it. Acta Orthop Scand 69: 56-62, 1998
 
10) Rubak JM: Reconstruction of articular cartilage defects with free periosteal grafts. Acta Orthop Scand 53: 175-782, 1982
PubMed
11) O'Driscoll SW, Keeley FW, Salter RB: The chondrogenic potential of free autogenous periostealgrafts for biological resurfacing of major full-thickness defects in joint surfaces under influence ofcontinuous passive motion. an experimental investigation in the rabbit. J Bone Joint Surg 68-A: 1017-1035, 1986
 
12) Wakitani S, Imoto K, Kimura T, et al: Hepatocyte growth factor facilitates repair of full thickness articular cartilage defect in rabbit knee. Acta Orthop Scand 68: 474-480, 1997
PubMed
13) Pittenger MF, Mackay AM, Beck SC, et al: Multilineage potential of adult human mesenchymalstem cells. Science 284: 143-147, 1999
 
14) Wakitani S, Goto T, Young RG, et al: Mesenchymal cell based repair of a large articular cartilage and bone defect. J Bone Joint Surg 76-A: 579-592, 1994
PubMed

治療と副作用

P.192 掲載の参考文献
1) Criswell LA, Henke C: What explains the variation among rheumatologists in their use of prednis-one and second line agents for the treatment of rheumatoid arthritis? JRheumatol 22: 829-835, 1995
 
2) Byron MA, Mowat AG: Corticosteroid prescribing in rheumatoid arthritis-the fiction and the fact. Br J Rheumatol 24: 164-166, 1985
PubMed
3) Fries JF: Toward an understanding of patient outcome measurement. Artritis Rheum 26: 697-704, 1983
 
4) American College of Rheumatology Ad Hoc Committee on Clinical Guidelines: Guidelines for the management of rheumatoid arthritis. Artritis Rheum 39: 713-722, 1996
 
5) Hickling P, Jacoby RK, Kirwan JR, et al: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 37: 930-936, 1998
PubMed
6) Hench PS, Kendall EC, Slocumb CH, et al: Effect of a hormone of the adrenal cortex (17-hydroxy-11dehydrocorticosterone: compound E) and of pituitary adrenocorticotrophic hormone on rheum atoid arthritis. Preliminary report. Proceedings of Staff Meetings of Mayo Clinic 24: 181-197, 1949
 
7) Joint Committee of the Medical Research Council and Nuffield Foundation: Acomparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. Br Med J 29: 1223-1227, 1954
 
8) Empire Rheumatism Council: Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Ann Rheum Dis 14: 353-367, 1955
 
9) Joint Committee of the Medical Research Council and Nuffield Foundation: A comparison of pre. dnisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 18: 173-187, 1959
PubMed
10) Joint Committee of the Medical Research Council and Nuffield Foundation: Acomparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis (a second report). Ann Rheum Dis 19: 331-337, 1960
 
11) Kirwan JR, Russell AS: Systemic glucocorticoid treatment in rheumatoid arthritis. Scand J Rheumatol 27: 247-251, 1998
PubMed
12) Bollet AJ, Black R, Bunim JJ: Major undesireble side-effects resulting from prednisolone and prednisone. JAMA 158: 459-463, 1955
 
13) Berntsen CA, Freyberg RH: Rheumatoid patients after five or more years of corticosteroid treatment: Acomparative analysis of 183 cases. Ann Intern Med 54: 938-953, 1961
PubMed
14) Andrade JRde, McCormick JN, Hill AGS: Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis 23: 158-162, 1964
 
15) 梅原千治: 歴史的背景.新副腎皮質ステロイド療法 (第2版) (梅原千治監修), pp7-12, 東京, 日本メルク萬有株式会社, 1983
 
16) Harris ED, Emkey RD, Nicholas JE, et al: Low dose prednisone therapy in rheumatoid arthritis; A double blind study. J Rheumatol 10: 713-721, 1983
 
17) Million R, Poole P, Kellgren JH, et al: Long term study of management of rheumatoid arthritis. Lancet I: 812-816, 1984
PubMed
18) van Gestel AM, Laan RFJM, Haagsma CJ, et al: 0ral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomised double-blind placebo-controlled trial. Br J Rheumatol 34: 347-351, 1995
 
19) McDougall R, Sibley J, Haga M, et al: Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls. J Rheumatol 21: 1207-1213, 1994
PubMed
20) Saag KG, Koehnke R, Caldwell JR, et al: Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events. Am J Med 96: 115-123, 1994
PubMed
21) Emery P, Salmon M: Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 54: 944-947, 1995
PubMed
22) Brook A, Corbett M: Radiographic changes in early rheumatoid disease. Ann Rheum Dis 36: 71-73, 1977
PubMed
23) Wilske KR, Healy LA: Remodeling the pyramid-a concept whose time has come, J Rheumatol 16: 565-567, 1989
 
24) Kirwan JR and Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 333: 142-146, 1995
 
25) Fries JF, Singh G: Glucocorticoids and joint destruction in rheumatoid arthritis (to the editor). NEngl J Med 333: 1569, 1995
 
26) Sherrer YS, Bloch DA, Mitchell DM, et al: Disability in rheumatoid arthritis: comparison of prog-nostic factors across three populations. J Rheumatol 14: 705-709, 1987
 
27) Porter D: Glucocorticoids and joint destruction in rheumatoid arthritis (to the editor). N Engl J Med 333: 1569, 1995
 
28) Boers M, Verhoeven AC, Markusse HM, et al: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350: 309-318, 1997
PubMed
29) Mottonen T, Hannonen P, Leirisalo-Repo M, et al: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis. Lancet 353: 1568-1573, 1999
PubMed
30) Boers M: Combination therapy in rheumatoid arthritis (letter). Lancet 354: 952, 1999
PubMed
P.202 掲載の参考文献
1) 小松原良雄: RAに対するDMARDsの投与の現状, 平成11年度大阪府特定疾患調査研究結果報告書 (投稿中)
 
2) 大正製薬株式会社, KE-298治験薬概要書, 第4版, 1996年5月28日
 
3) 山口友伸, 奥村良介, 田中啓市: 新規抗リウマチ薬T-614の開発にっいて. 第13回日本臨床リウマチ学会抄録集, pp49-50, 1991998
 
4) 藤沢薬品工業株式会社, FK506 (タクロリムス) の概要, 第4版, 1999年1月20日
 
5) Frust DE, Sherrer Y, Fleischmann RM, et al: Efficacy of FK506 in rheumatoid arthritis (RA), A6 month, dose-ranging study in RA patients failing Inethotrexate (MTX). ACR 1999, abstract 1206, 1999
 
6) Furst D, Cannon GW, Fox R, et al: Leflunomide 1998 United States scientific presentations. pp14-15, Haechst, 1998
 
7) Fox RT: Mechanism of action of Leflunomide in rheumatoid arthritis. J Rheumatoid 23 (supp 53), pp20-26, 1998
 
8) 鈴木泰夫: RAの新しい治療薬, レフルノミド (Leflunomide). RA&セラピー5, pp40-50, 1999
 
9) 小林義広: 慢性関節リウマチ患者を対象としたTA650 (Infliximab) へ開発動向. 第13回日本臨床リウマチ学会抄録集, pp51-52, 1998
 
10) 天野宏一: TNFレセプターIgG融合によるRAの治療.RA&セラピー 5, pp30-39, 1999
 
11) Immunex corporation. ENBREL (etanercept) 1999
PubMed
P.214 掲載の参考文献
1) Fukui S, Ohseto K, Shiotani M, et al: Referred pain distribution of the cervical zygaphophyseal joints and cervical dorsal rami. Pain 68: 79-83, 1996
 
2) Freemont AJ, Peacock TE, Goupille P, et al: Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet 350: 178-181, 1997
PubMed
3) Stanton HM, Janig W, Hassenbusch S, et al: Reflex sympathetic dystrophy; Changing concepts and taxonomy. Pain 63: 127-133, 1995
 
4) McLachlan EM, Janig W, Devor M, et al: peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 363: 543-546, 1993
PubMed
5) Nakamura S, Takahashi K, Takahashi Y, et al: The afferent pathways of discogenic low back pain. J Bone Joint Surg [Br] 78B: 606-612, 1996
 
6) Siddall P, Cousins MJ: Introduction to Pain Mechanisms. Implications for Neural Blockade. In: Neural Blockade in Clinical Anesthesia and Management of Pain (Eds, Cousins M, Bridenbaugh P), pp675-713, Phiradelphia, Lippincott-Raven Publishers, 1998
 
7) Hogan QH, Abram SE: Diagnostic and prognostic neural blockade. In: Neural Blockade in Clinical Anesthesia and Management of Pain (Eds, Cousins M, Bridenbaugh P), pp837-877, Philadelphia, Lippincott-Raven Publishers, 1998
 
8) Manning DC, Rowlingson JC: Back Pain and the Role of Neural Blockade. In: Neural Blockade in Clinical Anesthesia and Management of Pain (Eds, Cousins M, Bridenbaugh P), pp879-914, Philadelphia, Lippincott-Raven Publishers, 1988
 
9) 中崎和子: 硬膜外ブロック. ペインクリニック-神経ブロック法 (若杉文吉監修), pp79-88, 東京, 医学書院, 1988
 
10) McQuay H, Moore A: An evidence-based resource for pain relief. Oxford, Oxford University Press, 1988
 
11) McQuay HJ, Moore A: Epidural steroids for sciatica (letter; comment). Anaesth Intensive Care 24: 284, 1996
PubMed
12) 大瀬戸清茂: 神経根ブロック. ペインクリニック-神経ブロック法 (若杉文吉監修), pp221-227, 東京, 医学書院, 1988
 
13) 山上裕章, 湯田康正: 椎間関節ブロック. ペインクリニック-神経ブロック法 (若杉文吉監修), pp215-220, 東京, 医学書院, 1988
 
14) Bogduk N: International Spinal Injection Society guidelines for the performance of spinal Injection procedures. Part 1: Zygapophysial joint blocks. Clin J Pain 13: 285-302, 1997
PubMed
15) Schwarzer AC, Wang SC, O: Driscoll D, et al: The ability of computed tomography to identify a painful zygapophysial joint in patients with chronic low back pain. Spine 20: 907-912, 1995
 
16) Barnsley l, Lord SM, Wallis BJ, et al: Lack of effect of intraarticular corticosteroids for chronic pain in the cervical zygapophyseal joints (see comments). N Engl J Med 330: 1047-1050, 1994
 
17) Barnsley L, Bogduk N: Medial branch blockes are specific for the diagnosis of cervical zygapophy-seal joint pain. Reg Anesth 18: 343-350, 1993
 
18) 長沼芳和, 塩谷正弘: 高周波熱凝固法. ペインクリニック-神経ブロック法 (若杉文吉監修), pp250-253, 東京, 医学書院, 1988
 
19) North RB, Han M, Zahurak M, et al: Radiofrequency lumbar facet denervation; Analysis of prognostic factors. Pain 57: 77-83, 1994
PubMed
20) Lord SM, Barnsley L, Wallis BJ, et al: Percutaneous radiofrequency neurotomy for chronic cervical zygapophyseal-joint pain (see comments). N Engl J Med 335: 1721-1726, 1996
 
21) Stolker RJ, Vervest AC, Groen GJ: Percutaneous facet denervation in chronic thoracic spinal pain, Acta Neurochir (Wien) 122: 82-90, 1993
PubMed
22) 山上裕章, 大瀬戸清茂: 椎間板造影ペインクリニック-神経ブロック法 (若杉文吉監修), pp21-275, 東京, 医学書院, 1988
 
23) 若杉文吉: 星状神経節ブロック. ペインクリニック-神経ブロック法 (若杉文吉監修), pp16-24, 東京, 医学書院, 1988
 
P.222 掲載の参考文献
1) 寺本純: 各種神経痛に対するメキシレチン (メキシチール) の使用経験. 新薬と臨床40: 2585-2591, 1991
 
2) 表圭一, 並木昭義: ペインクリニックにおけるRSD. 医学のあゆみ175: 473-476, 1995
 
3) 奥山茂, 橋本早苗, 天沼二三雄ら: マウスの実験的慢性炎症性疼痛に対する各種鎮痛薬の作用, 日薬理誌 83: 513-521, 1984
Medical*Online
4) Walker JS, Chandler AK, Wilson JL, et al: Effect of μ-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats. Inflamm Res 45: 557-563, 1996
 
5) Binder W, Walker JS: Effect of the peripherally selective κ-opioid agonist, asimadoline, on adjuvant arthritis. Br J Pharm 124: 647-654, 1998
 
6) Zenz M, Strumpf M, Tryba M: Long-term oral opioid therapy in patient with chronic nonmalignant pain. J Pain Sympt Management 7: 69-77, 1992
 
7) Gonzales GR, Portenoy RK: Selection of analgesic therapies in rheumatoid arthritis. The role of opioid medications. Arthritis Care Res 6: 223-228, 1993
PubMed
8) Kanoff RB: Intraspinal derivery of opiates by an implantable, programmable pump in patients with chronic, intractable pain of nonmalignant origin. JAOA 94: 487-493, 1994
 
9) Moulin DE, Iezzi A, Amireh R, et al: Oral morphine eases chronic non-cancer pain, with little risk of addiction. Am J Health-Syst Pharm 53: 836-838, 1996
 
10) Ruoff GE: Slowing the initial titration rate of tramadol improves tolerability. Pharmacotherapy 19: 88-93, 1999
 
11) Perrot S, Bannwarth B, Bertin P, et al: Use of morphine in nonmalignant joint pain; The Limoges Recommendations. Rev Rhum (Engl Ed) 66: 571-576, 1999
PubMed
P.230 掲載の参考文献
1) アメリカ関節炎財団編 (日本リウマチ学会訳): 変形性関節症. リウマチ入門, 第11版 (日本語版), pp298-305, 1999 (原著は1997年)
 
2) Dieppe PA, Cooper C, Lim K, et al: Osteoarthritis and related disorders. In Rheumatology 2nd ed (Eds, Klippel JH, Dieppe PA), pp8. 1. 1-8. 9. 10, 1998
 
3) Dieppe PA, Cushnaghan J, Jasani MK, et al: Atwo year placebo controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee. BJ Rheum 35: 595-600, 1993
 
4) Hochberg MC, Altman RD, Brandt KD, et al: Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 38: 1541-1546, 1995
PubMed
5) Peyron JG: Preliminary chnical assessment of Nahyaluronate injection into human arthritic joints. Pathol Biol 22: 731-736, 1974
 
6) Chang RW, Falconer J, Stulberg SD, et al: Arandomized, controlled trial of arthroscopic surgery versus closed-needle joint lavage for patients with osteoarthritis of the knee. Arthritis Rheum 36: 289-296, 1993
 
7) Edelson R, Burks RT, Bloebaum RD: Short-term effects of knee washout for osteoarthritis. Am J Sports Med 23: 345-349, 1995
PubMed
8) Hilliquin P, LeDevic P, Menkes C-J: Comparison of the efficacy of nonsurgical synovectomy (synoviorthesis) and joint lavage in knee osteoarthritis with effusions. Rev Rheum (Engl ed) 63, 93-102, 1996
 
9) Hubbard MJS: Articular debridement versus washout for degeneration of the medial femoral condyle. A five-year study. J Bone Joint Surg 78. B: 217-219, 1996
 
10) 宗圓聰, 田中清介: 壮年期初期OAに対する関節洗浄. 関節外科17: 503-505, 1998
 
11) Ravaud P, Moulinier L, Giraudeau B, et al: Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee. Arthritis Rheum 42: 475-482, 1998
 
12) Ayral X, Dougados M: Joint lavage. Rev Rheum (Engl ed) 62: 281-287, 1995
 
P.236 掲載の参考文献
1) Collins WF: Historical introduction to spinal cord injury: The contributions of Allen, Riddoch, and Guttmann. In: Contemporary Management of Spinal Cord Injury (Eds, Benzel EC, Tator CH), pp1-7, Park Ridge, American Association of Neurological Surgeons, 1995
 
2) Bracken MB, Shepard MJ, Collins WF, et al: Arandomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury; Results of the second National Acute Spinal Cord Injury Study. N Engl J Med 322: 1405-1411, 1990
PubMed
3) 新宮彦助: 日本における脊損発生の疫学調査. 日本パラプレジア医学会誌6: 24-: 25, 1993
 
4) Nussbaum S, Maiman D: The spinal cord injury unit. In: Contemporary Management of Spinal Cord Injury (Eds, Benzel EC, Tator CH), pp247-253, Park Ridge, American Association of Neur ological Surgeons, 1995
 
5) Janssen L, Hansebout RR: Pathogenesis of spinal cord injury and newer treatments; A review. Spine 14; 23 32, 1989
 
6) Anthes DL, Theriault E, Tator CH: Characterization of axonal ultrastructural pathology following experimental spinal cord compression injury. Brain Research 702: 1-16, 1995
PubMed
7) Young W, Huang PP, Kume-Kick J: Cellular, ionic, and biomolecular mechanisms of the injury process. In: Contemporary Management of Spinal Cord Injury (Ed, Benzel EC, Tator CH), pp27-42, Park Ridge, American Association of Neurological Surgeons, 1995
 
8) Anderson DK, Waters TR, Means ED: Pretreatment with alpha tocopherol enhances neurologic recovery after experimental spinal cord compression injury. J Neurotrauma 5: 61-67, 1988
PubMed
9) Campbell JB, DeCrescito V, Tomasula JJ, et al: Effects of antifibrinolytic and steroid therapy on the contused spinal cord of cats. J Neurosurg 40: 726-733, 1974
 
10) Ross IB, Tator CH; Further studies of nimodipine in experimental spinal cord injury in the rat, J Neurotrauma 8: 229-238, 1991
 
11) Faden AI, Simon RP: A potential role for excitotoxins in the pathophysiology of spinal cord injury. Ann Neurol 23: 623-626, 1988
PubMed
12) Salzman SK, Puniak MA, Liu ZJ, et al: The serotoin antagonist mianserin improves functional re-covery following experimental spinal trauma. Ann Neurol 30: 533-541, 1991
 
13) Faden AI, Jacobs TP, Holaday JW: Opiate antagonist improves neurologic recovery after spinal injury. Science 211: 493-494, 1981
PubMed
14) Faden AI, Jacobs TP, Holaday JW: Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. N Engl J Med 305: 1063-1067, 1981
PubMed
15) Basso DM, Beattie MS, Bresnahan JC l Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol 139: 244-256, 1996
 
16) Basso DM, Beattie MS, Bresnahan JC, et al: MASCIS evaluation of open field locomotor scores; Effects of experience and teamwork on reliability. Multicenter animal spinal cord injury study. J Neurotrauma 13: 343-359, 1996
PubMed
17) Bracken MB, Shepard MJ, Holford TR, et al: Administration of methylprednisolone for 24 0r 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA 277: 1597-1604, 1997
PubMed
18) Geisler FH, Dorsey FC, Coleman WP: Recovery of motor function after spinal cord injury-a-randomized, placebo-controlled trial with GMl ganglioside. N Engl J Med 324: 1829-1838, 1991
 
19) Imanaka T, Hukuda S, Maeda T: The role of GM1-ganglioside in the injured spinal cord of rats; An immuno histochemical study using GM1-antisera. J Neurotrauma 13: 163-170, 1996
 
20) Bracken MB, Shepard MJ, Hellenbrand KG, et al: Methylprednisolone and neurological function one year after spinal cord injury. J Neurosurg 63: 704-713, 1985
 
21) 大谷清, 阿部弘, 角家暁ら: 急性期脊髄損傷に対するコハク酸メチルプレドニゾロンナトリウムの臨床成績. 脊椎脊髄ジャーナル7: 633-647, 1994
 
22) Anderson DK, Braughler JM, Hall ED, et al: Effects of treatment with U-746006F on neurological outcome following experimental spinal cord injury. J Neurosug 69: 562-567, 1988
PubMed
23) Schnell L, Schwab ME: Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 343: 269-272, 1990
PubMed
24) Tuszynski MH, Peterson DA, Ray J, et al: Fibroblasts genetically modified to produce nerve growth factor induce robust neuritic ingrowth after grafting to the spinal cord. Exp Neurol 126: 1-14, 1994
 
25) van de Meent H, Hamers FPT, Lankhorst AJ, et al: Beneficial effects of the melanocortin α-melanocyte stimulating hormone on clinical and neurophysiological recovery after experimental spinal cord injury, Neurosurg 40: 122-131, 1997
 
26) Zompa EA, Cain LD, Everhart AW, et al: Transplant therapy; Recovery of function after spinal cord injury. J Neurotrauma 14: 479-506, 1997
PubMed
27) Li Y, Field PM, Raisman G: Repair of adult corticospinal tract by transplants of olfactory enshe-athing cells. Science 277: 2000-2002, 1997
 
28) Falci S, Holtz A, Akesson E, et al: Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts; First clinical attempt. J Neurotrauma 14; 875-884, 1997
PubMed
29) Hayes KC: 4-Aminopyridine and spinal cord injury; Areview. Restorative Neurology and Neuroscience 6: 259-270, 1994
 
30) Fehlings MG, Nashmi R: Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury. Brain Research 736: 135-145, 1996
PubMed
31) Hansebout RR, Blight AR, Fawcett S, et al: 4-Aminopyridine in chronic spinal cord injury; A controlled, double-blind, crossover study in eight patients. J Neurotrauma 10: 1-18, 1993
PubMed
32) Saruhashi Y, Hukuda S, Maeda T: Acute aggregation of serotonin-immunoreactive platelets in the injured spinal cord of rat and change of serotonin content in the neural fibers. J Neurotrauma 7: 237-246, 1990
PubMed
33) Saruhashi Y, Hukuda S, Maeda T: Evidence for a neural source of acute accumulation of serotonin in platelets in the injured spinal cord of rats. An experimental study using 5, 6-dihydroxytryptam-ine treatment. J Neurotrauma 8: 121-128, 1991
 
34) Saruhahsi Y, Young W: Effect of mianserin on locomotory function after thoracic spinal cord hemisection in rats. Exp Neurol 129: 207-216, 1994
 
35) Saruhahsi Y, Young W, Perkins R: The recovery of 5-HT immunoreactivity in lumbosacral spinal cord and locomotor function after thoracic hemisection. Exp Neurol 139: 203-213, 1996
 
36) Saruhahsi Y, Young W, Sugimori M, et al: GABA increases refractoriness of adult rat dorsal column axons. Neuroscience 94: 1207-1212, 1999
 
37) Saruhahsi Y, Young W, Hassan AZ, et al: Excitatory and inhibitory effects of serotonin on spinal axons. Neuroscience 61: 645-653, 1994
 
38) Saruhahsi Y, Young W, Sugimori M, et al: Evidence for serotonin sensitivity of adult rat spinal axons; Studies using randomized double pulse stimulation. Neuroscience 80: 559-566, 1997
 
39) Saruhahsi Y, Young W, Hassan AZ: Calcium-mediated intracellular messengers modulate the ser-otonergic effects on axonal excitability. Neuroscience 81: 959-965, 1997
 
P.255 掲載の参考文献
1) Kingsley G: Microbial DNA in the synovium; Arole in aetiology or a mere bystander? Lancet 349: 1038-1039, 1997
PubMed
2) 根来茂: ライム病, リウマチ病セミナーII (七川歡次監修), pp65-73, 大阪, 永井書店, 1991
 
3) 井口和幸, 久保信彦, 川端真人: 日本におけるライム病の現況. 小児科診療9: 2019-2024, 1990
 
4) Kawabata M, Baba S, Iguchi K, et al: Lyme disease in Japan and its possible incriminated tick vec-tor, Ixodes persulcatus. J Infect Dis 156: 854, 1987
 
5) Priem S, Burmester GR, Kamradt T, et al: Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann Rheum Dis 57: 118-121, 1998
PubMed
6) Kamradt T, Lengl-Janssen B, Strauss AF, et al: Dominant recognition of a Borrelia burgdorferi outer surface protein A peptide by T helper cells in patients with treatment-resistant Lyme arthritis. Infect Immun 64: 1284-1289, 1996
 
7) Chen J, Field JA, Glickstein L, et al: Association of antibiotic treatment-resistant lyme arthritis with T cell response to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum 42: 1813-1822, 1999
 
8) Steere AC, Levin RE, Molloy PJ, et al: Treatment of Lyme arthritis. Arthritis Rheum 37: 878-888, 1994
PubMed
9) 西岡淳一: Reactive Arthritis. リウマチ病セミナーII (七川歡次監修), pp32-42, 1991
 
10) Hill Gaston JS, Cox C, Granfors K: Clinical and experimental evidence for persistent Yersinia infection in reactive arthritis. Arthritis Rheum 42: 2239-2242, 1999
 
11) Fryden A, Bengtsson A, Foberg U: Early antibiotic treatment of reactive arthritis associated with enteric infections; Clinical and serological study. Br Med J 301: 1299-1302, 1990
 
12) Leirisalo-Repo M: Therapeutic aspects of spondyloarthropathies; A review. Scand J Rheumatol 27: 323-328, 1998
PubMed
13) Braun J, Tuszewski M, Eggens U, et al: Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. 1. Screening of synovial fluid samples of patients with spondyloarthropathies and other arthritides. J Rheumatol 24: 1092-1100, 1997
PubMed
14) 松本明: クラミジアの分類と特性. 細胞内増殖菌による最近話題の感染症 (副島林造, 松本明編), pp 135-242, 東京, 医薬ジャーナル社, 1989
 
15) Everett KD, Bush RM, Anderson AA: Emended description of the order Chlamydiales, proposal of parachlamydiaceae fam, nov. and Simkaniaceae fam. Nov., each containing one monotypic genus, revised toxonomy of the family Chlamydiae, including a new genus and five new species, and stan-dards for the identification of organisms. Int J Syst Bacteriol 49: 415-440,. 1999
 
16) 岸本寿男: クラミジアニューモニエ感染症. 臨床と微生物25: 143-151, 1998
 
17) Lanham JG, Doyle DV: Reactive arthritis following psittacosis. Br J Rheumatol 23: 225-226, 1984
PubMed
18) Bardin T, Enel C, Cornelis F, et al: Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum 35: 190-194, 1992
 
19) Lauhio A, Leirisalo-Repo M, Lahdevirta J, et al: Double-blind, placebocontrolled study of three-month treatment with lymecycline in reactive arthritis, with special reference to chlamydia arthritis. Arthritis Rheum 34: 6-14, 1991
 
20) Wollenhaupt J, Hammer M, Pott HG, et al: A double-blind placebo-controlled cornparison of 2 weeks versus 4 months treatment with doxycycline in Chlamydia-induced arthritis. Arthritis Rheum 40: S143, 1997
 
21) Beutler AM, Hudson AP, Whittum-Hudson JA: Chlamydia trachomatis can persist in joint tissue after antibiotic treatment in chronic Reiter's syndrome/reactivearthritis. J Clin Rheumatol 3: 125-130, 1997
PubMed
22) Gran JT, Hjetland R, Andreassen AH: Pneumonia, myocarditis and reactive arthritis due to Chlamydia pneumoniae. Scand J Rheumatol 22: 43-44, 1993
PubMed
23) Braun J, Laitko S, Treharne J, et al: Chlamydia pneumoniae-anew causative agent of reactive arthritis and undifferentiated oligoarthritis. Ann Rheum Dis 53: 100-105, 1994
 
24) Wilkinson NZ, Kingsley GH, Sieper J, et al: Lack of correlation between the detection of chlamydia trachomatis DNA in synovial fluid from patients with a range of rheumatic diseases and the presence of an antichlamydial immune response, Arthritis Rheum 41: 845-854, 1998
PubMed
25) Pott HG, Wittenborg A, Junge-Hulsing G: Long-term antibiotic treatment in reactive arthritis. Lancet (Jan 30): 245-246, 1988
 
26) Mattila L, Leirisalo-Repo M, Pelkonen P, et al: Reactive arthritis following an outbreak of Salmonella Bovismorbificans infection. J Infect 36: 289-295, 1998
PubMed
27) Leirisalo-Repo M, Helenius P, Hannu T, et a (: Long term prognosis of reactive salmonella arthritis. Ann Rheum Dis 56: 516-520, 1997
PubMed
28) Sieper J, Fend (er C, Laitko S, et al: No benefit of long-term ciprofloxacin treatment in patientswith reactive arthritis and undifferentiated oligoarthritis. Arthritis Rheum 42: 1386-1396, 1999
 
29) Toivanen A, Yli-Kerttula T Luukkainen R, et al: Effect of antirnicrobial treatment on chronic reactive arthritis. Clin Exp Rheumatol 11: 301-307, 1993
PubMed
30) Zhang Y, Gripenberg-Lerche C, Soderstrom K, et al: Antibiotic prophylaxis and treatment of reac-tive arthritis. Lessons from an animal model. Arthritis Rheum 39: 1238-1243, 1996
 
31) Pugh MT, Southwood TR: Tuberculous rheumatism, Poncet disease; Asterile controversy? (editorial), Revue du Rhum Ed Fr 60: 855-860, 1993
 
32) Jansen TLTA, Janssen M, de Jong AJL: Reactive arthritis associated with group C and group G β-hemolytic streptococci. J Rheumatol 25: 1126-1130, 1998
 
33) Kocar IH, Caliskaner Z, Pay S, et al: Clostridium difficile infection in patients with reactive arthritis of undetermined etiology. Scand J Rheumatol 27: 357-362, 1998
PubMed
34) Cooper SM: A perspective on the use of minocycline for rheumatoid arthritis. J Clin Rheumatol 51 233-238, 1999
 
35) O'Dell JR: Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis? Drugs 57: 279-282, 1999
 
36) Golub LM, Lee HM, Lehrer G, et al: Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res 18: 516-524, 1983
 
37) Greenwald RA: Treatment of destructive arthritic disorders with MMP inhibitors; Potential role of tetracyclines. Ann N Y Acad Sci 732: 181-198, 1994
PubMed
38) Nordstrom D, Lindy O, Lauhio A: Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int 17: 175-180, 1998
PubMed
39) Sewell KL, Breedveld FC, Furrie E, et al: The effect of minocycline in rat models of inflammatory arthritis; Correlation of arthritis suppression with enhanced T cell calcium flux. Cell Immunol 167: 195-204, 1996
 
40) Kloppenburg M, Brinnkman BMN, de Rooij-Dijk HH, et al: The tetracycline derivative minocycline differentially affects cytokine production by monocytes and T lymphocytes. Antimicrob Agents Chernother 40: 934-940, 1996
 
41) Amin AR, Attur MG, Thakker GD, et al: Anovel mechanism of action of tetracyclines; Effects on nitric oxide synthases. Proc Natl Acad Sci USA 93: 14014-14019, 1996
 
42)一酸化窒素(NO)と関節炎. リウマチ病セミナーXI, p166-172, 大阪, 永井書店, 2000
 
43) Sorsa T, Saari H, Konttinen YT, et al: Human neutrophil collagenase and oxygen derived free radicals. N Engl J Med 321: 327-328, 1989
 
44) Gilbertson-Beadling S, Powers EA, Stamp-Cole M: The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 36: 418-424, 1995
PubMed
45) williams S, wakisaka A, zeng QQ, et al: Minocycline prevents the decrease in bone mineral density and trabecular bone in ovariectomized aged rats. Bone 19: 637-644, 1996
 
46) Breedveld FC, Dukmans BAC, Mattie H: Minocycline treatment for rheumatoid arthritis. An open dose finding study. J Rheumatol 17: 43-46, 1990
 
47) Langevitz P, Bank I, Zemer D, et al: Treatment of resistant rheumatoid arthritis with minocycline; An open study. J Rheumatol 19: 1502-1504, 1992
 
48) Kloppenburg M, Breedveld FC, Terwiel JP, et al: Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial. Arthritis Rheum 37: 629-636, 1994
PubMed
49) Tilley BC, Alarcon GS, Heyse SP, et al for the MIRA trial group: Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. Ann Intern Med 122: 81-89, 1995
PubMed
50) O'Dell JR, Haire CE, Palmer W, et al: Treatment of early rheumatoid arthritis with minocycline or placebo; Results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum 40: 842-848, 1997
 
51) O'Dell JR, Paulsen G, Haire CE, et al: Treatment of early seropositive rheumatoid arthritis with minocycline. Four-year follow up of a double-blind, placebocontrolled trial. Arthritis Rheum 42: 1691-1695, 1999
 
52) 川中紀邦, 山村昌弘, 橋本洋夫ら: 慢性関節リウマチに対するミノサイクリンの有用性の検討. リウマチ38: 801-809, 1998
 
53) Matsuura T, Shimizu Y, Fujimoto H, et al: Minocycline-related lupus. Lancet 340: 1553, 1992
PubMed
54) Elkayam O, Yaron M, Caspi D: Minocycline-induced autoimmune syndromes; An overview. Semin Arthritis Rheum 28: 392-397, 1999
PubMed
55) Boudreaux JP, Hayes DH, Mizrahi S, et al: Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proc 25: 1873, 1993
PubMed
56) Angulo JM, Sigal LH, Espinoza LR: Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin Arthritis Rheum 28: 187-192, 1998
PubMed
57) McKendry RJR: Is rheumatoid arthritis caused by an infection? Lancet 345: 1319-1320, 1995
 
P.264 掲載の参考文献
1) Hawley DJ: Psyco-educational intervention in the treatment of arthritis. Baliere's Clin Rheumatol 9: 803 823, 1995
 
2) Lorig K, Gonzalez V: The integration of therapy withpractice. Health Education Quartery 9: 355-368, 1992
 
3) Parker JC, Iverson G, Smarr KL, et al: Cognitive-behavioral approach to pain management in rheumatoid arthritis. Arthritis Care Res 6: 209-212, 1993
 
4) Radojevic V, Nicassio PM, Weisman MH: Behavioral intervation with and without family support for arthritis. Behavioral Therapy 23: 13-30, 1992
 
5) O'Leary A, Shoor S, Lorig K, et al: Acognitive-behavioral treatment for rheumatoid arthritis. Health Psychology 7: 537-544, 1995
 
6) Rene J, Weinleson M, Mazzuca SA, et al: Reduction of joint pain in patients,with knee osteoarthritis who recieved monthly telephone calls from lay personal and whose medical treatment regimens have remained stable. Arthritis Rheum 35: 511-515, 1992
 
7) Neuberger GS, Smith KV, Black SO, et al: Promotery self-care in clients, with arthritis. Arhtritis Care Res 6: 141-148, 1993
 
8) 0rr RM, Bratton GN: The effect of an inpatient arthritis rehabilitation program on self-assistedfunctional ability. Rehabilitatiion Nursing 17: 306-316, 1992
 
9) Superio-Cabuslay E, Ward M, Lorig K: Patient education interventions in osteoarthritis and rheumatoid arthritis; Ameta-analytic comparison with nonsteroidal anti inflammmatory drug treatment. Arthritis Care Res 9: 292-301, 1996
 
10) Brus HLM, van de Laar MAH, Taal E, et al: Effect of patient education on compliance with basic treatment regimens and health in recent onset activerheumatoid arthritis. Ann Rheum Dis 57: 146-151, 1998
 
11) Lindroth Y, Bauman A, Brooks DM, et al: A 5year follow-up of a controlled trial of an arthritiseducation programme. Brit J Rheumatol 34: 697-652, 1995
 
12) Parker JC, Frank RG, Beck NC, et al: Pain management in rheumatoid arthritis patients; A cognitive-behavioral approach. Arthritis Rheuma 31: 593-601, 1988
 
13) Theodora PM, Vlieland V, Hazes JMM: Efficacy of multidisciplinary team care programs in rheumatoid arthritis; Semin Arthritis Rheum 26: 100-122, 1997
 
14) Simeori E, Bauman A, Stenmark J, et al: Evaluation of a community arthritis program in Australia; 12 Dissemination of a developed program. Arthritis Care Res 8: 102-107, 1990
 
15) Lorig K, Mazonson P, Holman H: Evidence suggesting that health education for self-managementin patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum 36: 439-446, 1993
 
16) Lambert CM, Hurst NP, Forbes JE, et al: Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomized control clinical and economic evaluation. BMJ 316: 965-969, 1998
 
17) Mazzuca SA: Economic evaluation of arthritis patient education. Bull Rheum Dis 43: 6-8, 1994
PubMed
18) 前田晃, 岡崎文江: 慢性関節リウマチの疾患認識調査. 大阪特定疾患研究報告書平成11年度骨・関節難病研究会, 印刷中
 
19) Etchells E: Asafe, effective ajunctive treatment for arthritis, and pretty much every other condition you'll ever treat. J Rheumatol 26: 1647-1649, 1999
 
20) Roman K, Dorgle D, Grifiths I: Standard of care for arthrits; Pointing the way forward. Brit J Rheumatol 37: 242-245, 1998
 
21) Lorig KR: Patient educatioin: Treatment or nice extra. Brit J Rheumatol 37: 703-706, 1998
 
22) Lorish CD, Pantaugh ML: Patient education in rheumatology. Current opinion in rheumatol 9: 106-111, 1997
PubMed

手術

P.273 掲載の参考文献
1) Chang Y, Oka M, Nakamura T: Bone formation and remodeling around implanted materials under load bearing conditions. Clin Mat 17: 181-187, 1995
 
2) Chang Y, Oka M, Kobayashi T, et al: Significance of interstitial bone ingrowth under load-bearing conditions; A comparison between solid and porous implant materials. Biomaterials 17: 1141-1148, 1996
 
3) Chang Y, Oka M, Nakamura T: Bone remodeling around implanted ceramics. J Biomed Mat Res 30 1117-157, 1996
 
4) Delecrin J, Oka M, Kumar P: Joint reactions against polymer particles; PVA-H versus UHMWPE. JJap Orthop Ass 64: S1395, 1990
 
5) 藤野まどか, 岡正典, 永田和宏: 培養軟骨細胞はフィブネクチンのRGDS配列に結合するか? 日整会誌 62: 765S, 1988
 
6) 速水尚, 岡正典, 池内健ら: 関節材料の衝撃吸収能に関する研究III-PVA-Hydrogelの損失係数に及ぼす分子量と含水率の効果-. 生体材料11: 79-84, 1993
 
7) Hayami T, Oka M, Ikeuchi K, et al: The Energy-Absorbing Function of Cancellous Bone and Its Influence on the Loosening of Artificial Joints. Clinical Biomechanics and Related Research, pp138-152, 1994
 
8) 池内健, 岡正典, 魏国雄:生体関節における変形とスクイーズ膜交換に関する実験的研究. 日本機械学会論文集 (C論) 55 (316): 2123-2130, 1989
 
9) 村瀬晃平, 岡正典, 堤定美ら: 3次元衝撃FEM解析による股関節の負荷機構の研究. 生体材料12: 173-183, 1994
 
10) Noguchi T, Yamamuro T, Oka M, et al: Poly (Vinyl Alcohol) Hydrogel as an artificial articular cartilage; Evaluation of Biocompatibility. J Appl Biomat 2: 101-107, 1991
 
11) Noguchi T, Oka M, Fujino M, et al: Repair of Osteochondral Defects With Grafts of Cultured Chondrocytes Comparison of Allografts and Isografts. Clin Orthop 302: 251-258, 1994
PubMed
12) 岡正典: 人工関節軟骨 (整形トピック). 整形外科34: 1124, 1983
 
13) 岡正典: 人工関節材料の現状と未来. リウマチ28: 263-273, 1988
 
14) 岡正典: 関節軟骨のバイオレオロジー. 日本バイオレオロジー学会誌3: 152-163, 1989
 
15) Oka M, Noguchi T, Kumar P, et al: Development of an artificial articular cartilage. Clinical Mat 6: 361-381, 1990
 
16) 岡正典: 人工関節軟骨の開発. 病態生理10: 52-58, 1991
 
17) Oka M, Ikeuchi K, Tsutsumi S, et al: Biomechanics of natural and artificial joints. Biomechanics (Eds by Niwa, SM. Perren), pp282-298, 1992
 
18) Oka M: Load-bearing mechanism of natural and artificial joints. Hip Biomechanics Spring. Verl, pp255-263, 1993
 
19) 岡正典: 海綿骨の衝撃緩衝機能. The Bone 9: 70-86, 1994
 
20) Oka M, Chang Y, Nakamura T, et al: Bone Remodeling Around Implanted Materials. Clinical Biomechanics and Related Research, pp124-137, 1994
 
21) 岡正典: 生体関節と人工関節のバイオメカニクス. 日整会誌67: 535-547, 1993
 
22) 岡正典: 人工股関節モデル改革への提言. OS NOW 13: 90-96, 1994
 
23) 岡正典: 関節軟骨のバイオメカニクス. 臨床リウマチ7: 60-81, 1995
 
24) Oka M, Chang Y, Nakamura T: Bone remodeling around implanted ceramics. Bioceramics 8: 103-106, 1995
 
25) Oka M: Mise au point d'un cartilage articulaire artificial. Cahiers d'enseigement de la SOFCOT 57; (Biomateriaux de Substitution de L'os et du Cartilage): 62-74, 1996
 
26) Oka M, et al: Synthetic osteochondral replacement of the femoral articular surface. J Bone & Joint Surg 79-B: 1003-1007, 1997
 
27) 岡正典, 由良茂人: 人工椎間板の開発. 脊椎・精髄12: 429-434, 1999
 
28) 新谷浩也, 田中高廣, 坂口一彦ら: 生体関節と人工関節の潤滑機構 (第5報). 日本臨床バイオメカニクス学会誌14: 225-228, 1992
 
29) 田中高廣, 岡正典, 速水尚ら: 関節の緩衝特性に関する研究. 生体材料11: 19-30, 1993
 
30) 外村孝次, 岡正典, 堤定美ら: 関節面の接触を考慮した応力解析: 表面置換型人工股関節のデザインについて. 生体材料10: 122-136, 1992
 
31) 牛島三七十郎, 岡正典, 玄丞烋ら: 人工関節軟骨の耐摩耗性向上に関する研究. 生体材料14: 201-210, 1996
 
32) Vacanti CA, Kim W, Schloo B, et al: Joint resurfacing with cartilage grown in situ from cell-polymer structures. Am J of Sports Med 22: 485-488, 1994
 
P.277 掲載の参考文献
1) 政田和洋: 解説: 新しい人工指関節. リウマチ科20: 497-503, 1998.
 
2) Stothard J, Thompson AE, Sherrls D: Correction of ulnar drift during silastic metacarpophalangeal joint arthroplasty. J Hand Surg 16B: 61, 1991
 
3) Swanson AB: Flexible implant arthroplasty for arthritic finger jonts; Rationale and resulta of treatment. J Bone Joint Surg 54A: 435, 1972
 

書評

最近チェックした商品履歴

Loading...